Illustrativt foto: Unsplash+

Duchenne Muskeldystrofi (DMD) er en alvorlig, progressiv, sjælden genetisk sygdom, der fører til tab af muskelstyrke. Sygdommen er forårsaget af mutationer i det gen, der er ansvarligt for at producere dystrophin, et protein, der beskytter muskelfibre mod nedbrydning. For bedre at forstå de daglige udfordringer, som patienter står over for, og hvordan de overvinder dem, anbefaler vi at læse det pædagogiske materiale og den inspirerende historie om Sachin Munshi, der lever med denne diagnose.

I moderne medicin er et af de lovende områder for DMD-støtte exon skipping-terapi. Denne metode „reparerer“ ikke det beskadigede gen permanent, men gør det muligt for cellen, når den læser genetiske instruktioner, at „hoppe over“ det defekte segment. Som et resultat produceres en forkortet, men delvist funktionel version af dystrophin-proteinet.

FORZETTO Forsøgsdesign

Bioteknologivirksomheden Dyne Therapeutics er begyndt at rekruttere til et fase 3 klinisk forsøg ved navn FORZETTO (internationalt registernummer NCT07608432). Det undersøger det eksperimentelle lægemiddel zeleciment rostudirsen (DYNE-251). Vigtig præcisering: dette lægemiddel udvikles ikke til alle DMD-patienter, men udelukkende til dem, hvis genetiske mutationer er egnede til exon 51-skipping (exon 51-skipping).

Forsøgets status er i øjeblikket „Rekruttering“. Vigtige forsøgsparametre inkluderer:

• Deltagere: Projektet vil involvere 90 mandlige patienter i alderen 4 til 18 år med en bekræftet DMD-diagnose og den tilsvarende mutation.
• Intervention: Deltagerne vil modtage DYNE-251 som en intravenøs infusion en gang hver 4. uge.
• Evaluerede resultater: Hovedmålet med forsøget er at vurdere behandlingens indvirkning på patienternes fysiske motoriske funktion, samt at bekræfte lægemidlets sikkerhed og dets evne til at øge dystrophinproduktionen i muskler.

Hvorfor overgangen til fase 3 er vigtig

Lanceringen af fase 3 betyder, at lægemidlet har vist en opmuntrende sikkerheds- og aktivitetsprofil i tidligere stadier. Selvom exon skipping-teknologi ikke er en komplet kur, repræsenterer fremkomsten af nye behandlingsmuligheder (især med et praktisk administrationsskema hver 4. uge) for familier, der står over for Duchenne muskeldystrofi, et afgørende skridt fremad.

Primær kilde (register for kliniske forsøg): ClinicalTrials.gov: NCT07608432 (FORZETTO).

Pædagogisk materiale om sygdommen: Rare Disease Day: Resilience in the face of Duchenne Muscular Dystrophy.

Illustrativt foto: Rauf Alvi / Unsplash+

At overholde fasten i den hellige måned ramadan indebærer fuldstændig afholdenhed fra mad og drikke i de lyse timer. For millioner af mennesker med type 2-diabetes betyder dette en væsentlig ændring i deres kost- og medicineringsregime, hvilket kan føre til farlige blodsukkerudsving eller hypoglykæmi. Håndtering af diabetes i denne periode kræver særlig opmærksomhed og omhyggeligt valg af terapi.

GLP-1-receptoragonister har vist sig effektive til at sænke blodsukker og kropsvægt; de fleste af dem kræver imidlertid injektioner. Medicinalvirksomheden Eli Lilly udvikler orforglipron (LY3502970) — en ny oral (pillebaseret) non-peptid GLP-1-receptoragonist, der tages én gang dagligt. I tidligere fase 3-forsøg har det allerede vist evnen til at reducere HbA1c og vægt, men dets anvendelse under langvarig faste i dagtimerne er endnu ikke blevet undersøgt.

ACHIEVE-RAM-studiets design

For at lukke dette hul i de kliniske data er et nyt multinationalt fase 3-studie kaldet ACHIEVE-RAM (registernummer NCT07613307) blevet registreret. Sponsoren er Eli Lilly and Company.

Hovedmålet med projektet er at evaluere sikkerheden og effekten af orforglipron hos voksne patienter med type 2-diabetes, som planlægger at faste under ramadanen. Ifølge registret er forsøgets status "Rekrutterer endnu ikke" (Not yet recruiting). Den planlagte start er fastsat til juli 2026, med afslutning i maj 2027.

• Deltagere: Forsøget planlægger at tilmelde 130 patienter med type 2-diabetes.
• Geografi: Projektet vil blive gennemført i et multinationalt format. Listen over deltagende lande omfatter Indien, Saudi-Arabien, Sydafrika og De Forenede Arabiske Emirater (UAE).

Hvorfor dette betyder noget for den virkelige praksis

ACHIEVE-RAM er et godt eksempel på, hvordan kliniske forsøg tilpasses patienternes virkelige liv. For endokrinologer i muslimske lande (og nationer med store muslimske diasporaer) er det afgørende at have evidensbaserede protokoller for ordination af nye medikamenter. Hvis en oral GLP-1 viser god tolerabilitet og stabil glykæmisk kontrol uden høj risiko for hypoglykæmi under faste i dagtimerne, kan det forenkle patienthåndteringen under ramadanen betydeligt.

Primær kilde (register for kliniske forsøg): ClinicalTrials.gov: NCT07613307 (ACHIEVE-RAM).

Illustrativt foto: Getty Images / Unsplash+

Præeklampsi (svangerskabsforgiftning) er en af de farligste graviditetskomplikationer, forbundet med forhøjet blodtryk og alvorlige sundhedsrisici for både mor og barn. Ifølge de nuværende anbefalinger fra US Preventive Services Task Force (USPSTF) rådes gravide kvinder med høj risiko for at udvikle svangerskabsforgiftning til at tage lavdosis aspirin (81 mg/dag) fra 12. graviditetsuge. Beslutningen skal dog altid træffes af en læge under hensyntagen til den individuelle risikoprofil og mulige kontraindikationer.

I den virkelige kliniske praksis genkender læger dog ikke altid de nødvendige risikofaktorer i patientens anamnese i tide, hvorved de går glip af muligheden for forebyggende behandling. For at bygge bro over denne kløft mellem medicinske retningslinjer og rutinemæssig pleje er et nyt klinisk studie blevet registreret i USA under identifikationen NCT07614893.

Projektet, der er initieret af forskere på Massachusetts General Hospital (Mass General Brigham), tester ikke et nyt lægemiddel, men derimod et digitalt værktøj — et klinisk beslutningsstøttesystem (Clinical Decision Support, CDS) integreret i den elektroniske patientjournal (EPJ).

Hvordan studiet vil foregå

Dette er et pragmatisk klinisk studie, der vil finde sted i standard ambulante omgivelser. I øjeblikket er projektets status "Rekrutterer endnu ikke" (Not yet recruiting). Interventionen er struktureret som følger:

• Intervention: En algoritme indbygget i EPJ vil analysere patientens data. Hvis systemet identificerer højrisikofaktorer for præeklampsi, vil den behandlende læge modtage en automatisk pop-up-meddelelse med en anbefaling om at overveje at ordinere lavdosis aspirin.
• Kontrolgruppe: Læger, der yder pleje i henhold til standardprotokollen (Standard of Care), uden yderligere automatiske systempåmindelser.
• Hovedmål: At evaluere, om en sådan digital notifikation statistisk signifikant øger andelen af korrekt udvalgte patienter, som får ordineret rettidig forebyggelse.

Hvorfor dette er vigtigt

Ordination af lavdosis aspirin er en simpel, tilgængelig og dokumenteret sikker foranstaltning, men den virker kun, når den anvendes i tide. Integration af smarte notifikationer direkte i fødselslægens arbejdsgang kan være det manglende led, der hjælper læger, som har strenge tidsbegrænsninger under konsultationerne, med ikke at overse vitale forebyggende tiltag.

Primær kilde (register for kliniske forsøg): ClinicalTrials.gov: NCT07614893.

Yderligere kontekst: USPSTF-anbefaling til forebyggelse af præeklampsi.

Illustrativt foto: Towfiqu Barbhuiya / Unsplash+

Moderne kliniske retningslinjer beskriver klart, hvordan man beskytter nyrerne og hjertet hos patienter med type 2-diabetes. Men i den virkelige daglige praksis udskriver læger ikke altid livsvigtige terapier — såsom SGLT2-hæmmere eller GLP-1-receptoragonister — i tide. Kløften mellem medicinsk teori og den faktiske patientbehandling er fortsat en stor sundhedsudfordring.

For at finde en praktisk løsning er et nyt klinisk studie kaldet RAPID-CKM (internationalt registernummer NCT07605390) blevet registreret i USA. Projektet er initieret af Baylor Research Institute. Det unikke ved studiet ligger i, at det ikke tester virkningen af et nyt lægemiddel, men ydeevnen af et digitalt værktøj: automatiske kliniske råd i patientens elektroniske journal (EPJ).

Studiedesign og detaljer

RAPID-CKM er et pragmatisk randomiseret studie (pragmatic randomized trial), hvilket betyder, at det udføres i virkelige kliniske omgivelser frem for i et idealiseret miljø. I øjeblikket er projektets status "Rekrutterer endnu ikke" (Not yet recruiting). De vigtigste parametre for forsøget inkluderer:

• Deltagere: Praktiserende læger og deres patienter, der lider af type 2-diabetes, kronisk nyresygdom (CKD) og albuminuri.
• Intervention: Integration af målrettede Best Practice-rådgivninger (Best Practice Advisories) i det elektroniske EPJ-system Epic. Lige under konsultationen vil lægen modtage en diskret påmindelse, der indikerer, at denne patient er berettiget til specifik nyrebeskyttende behandling (Guideline-Directed Medical Therapy, GDMT).
• Kontrolgruppe: Læger, der yder pleje i henhold til standardprotokollen (Standard of Care), uden yderligere pop-up-advarsler.
• Primært endepunkt (Primary Outcome): Vurdering af, om det digitale "puf" øger andelen af patienter, som får ordineret de anbefalede mediciner inden for 6 måneder efter besøget.

Hvorfor fokus på CKM-syndrom er vigtigt

Forkortelsen CKM står for Cardiovascular-Kidney-Metabolic syndrom. Dette er et koncept, der aktivt fremmes af American Heart Association (AHA) og nefrologer, som understreger, at diabetes, fedme, nyresygdom og kardiovaskulære risici er uløseligt forbundet og kræver en omfattende tilgang.

For patienter med CKM-syndrom kan den tidlige ordination af den rigtige medicin i høj grad bremse nyreskader og forhindre hjerteanfald. På grund af strenge tidsbegrænsninger under konsultationer er læger imidlertid ofte tvunget til kun at fokusere på aktuelle akutte klager, og går dermed glip af muligheden for forebyggende ordination. RAPID-CKM har til formål at bekræfte, om automatisering kan lukke dette hul.

Hvad kan man forvente af resultaterne

Hvis studiet beviser, at enkle og rettidige EPJ-notifikationer statistisk signifikant øger hyppigheden af korrekte ordinationer, kan denne erfaring opskaleres. At integrere sådanne algoritmer i kliniksoftware kan blive en af de hurtigste og billigste måder at forbedre kvaliteten af behandlingen for patienter med diabetes og CKD.

Primær kilde (register for kliniske forsøg): ClinicalTrials.gov: NCT07605390 (RAPID-CKM).

Yderligere information om sygdomssammenhænge: National Kidney Foundation: CKM Syndrome.

Illustrativt foto: Getty Images / Unsplash+

Knæartrose er en af de mest almindelige årsager til kroniske smerter og nedsat mobilitet. Når piller, injektioner og fysioterapi ikke længere hjælper, bliver ledudskiftningskirurgi standardløsningen. Et nyt studie offentliggjort i tidsskriftet Radiology evaluerer et minimalt invasivt alternativ til patienter, der endnu ikke er klar til at få et nyt knæ.

Metoden kaldes genikulær arterieembolisering (GAE). Under proceduren indfører interventionelle radiologer et mikrokateter gennem en lille punktur i de blodkar, der forsyner ledkapslen. Derefter injiceres resorberbare mikrosfærer i de unormalt overvoksede små arterier, der opretholder kronisk inflammation. Dette begrænser blodgennemstrømningen til det betændte væv og hjælper med at reducere smerter.

Hvad studieresultaterne viste

Forskere gennemførte et prospektivt observationelt studie på et enkelt center med 194 patienter. I alt blev der udført 239 genikulære emboliseringsprocedurer. Ifølge forfatterne var den tekniske succesrate for interventionen 100 %.

Smerter blev vurderet ved hjælp af en numerisk vurderingsskala (NRS) fra 0 til 10. Før proceduren var den mediane smertescore 7. Tolv måneder efter embolisering faldt denne score til 3.

Klinisk signifikant smerteforbedring efter et år blev opnået af 80 % af patienterne. Derudover udfyldte deltagerne KOOS-spørgeskemaet for at evaluere ledfunktion i dagligdagen og livskvalitet. Afhængigt af den specifikke underskala i spørgeskemaet blev der bemærket en forbedring, der oversteg den minimalt klinisk vigtige forskel, hos 55-80 % af deltagerne.

Hvor sikkert er det

Proceduren demonstrerede en gunstig sikkerhedsprofil. Milde, selvopløsende bivirkninger blev registreret i 6,7 % af tilfældene. Der blev ikke registreret moderate eller alvorlige komplikationer i opfølgningsperioden.

Begrænsninger og konklusioner for patienter

Det er vigtigt at forstå, at embolisering ikke regenererer ødelagt brusk eller vender udviklingen af artrose. Det er ikke en garanteret smertelindring for hver patient, og det er heller ikke en bevist måde at "udskyde kirurgi i årevis".

Desuden var det offentliggjorte arbejde et observationelt studie. Det manglede en kontrolgruppe (for eksempel patienter, der fik placebo eller en sham-procedure), hvilket er en væsentlig begrænsning for at vurdere den sande effekt af smertelindringen.

Ikke desto mindre indikerer resultaterne, at genikulær embolisering kan blive en vigtig mellemløsning for en specifik gruppe af patienter: dem, der ikke længere drager fordel af konservativ terapi, men for hvem kirurgi endnu ikke er indiceret eller ønskeligt.

Primær kilde: Radiological Society of North America (RSNA), videnskabeligt tidsskrift Radiology.

Illustrativt foto: Getty Images / Unsplash+

Lægemidler i GLP-1-klassen er blevet berømte for deres succesfulde behandling af type 2-diabetes og imponerende resultater inden for vægttab. Men efterhånden som millioner af mennesker er begyndt at bruge dem, stiller læger i stigende grad et andet spørgsmål: Hvad sker der med den reproduktive sundhed, når en patients vægt, blodsukkerniveau, insulinresistens og hormonbalance forbedres?

Det endelige svar er endnu ikke klar. Flere nylige videnskabelige rapporter har dog øget interessen for fertilitetsemnet — hos både kvinder og mænd. Det er vigtigt at slå fast med det samme: GLP-1-medicin er ikke en behandling mod infertilitet og bør ikke betragtes som en måde at "øge chancerne for graviditet" uden streng lægelig overvågning.

Hvad data for kvinder viste

En af de nye grunde til diskussion er knyttet til RESTORE-forskningsprogrammet, som gennemføres på University of Colorado (CU Anschutz). Projektet undersøger brugen af semaglutid hos piger og kvinder med svær overvægt og PCOS/PMOS. PCOS står for polycystisk ovariesyndrom, og PMOS bruges som en opdateret betegnelse for en tilstand, der kombinerer menstruationsuregelmæssigheder, forhøjede androgener, risiko for infertilitet og dybe metaboliske problemer.

En tidlig proof-of-concept-analyse fokuserede på deltagere i alderen 12-35 år, som opnåede mindst 10 % reduktion i kropsvægt under behandlingen. Ifølge CU Anschutz-forskningsteamet oplevede nogle patienter reproduktive forbedringer (herunder genoprettelse af ægløsning) hurtigere end forventet, hvorfor holdet præsenterede foreløbige resultater inden hovedstudiet afsluttes.

Pointen med disse data er ikke, at semaglutid direkte "helbreder infertilitet." En mere forsigtig og videnskabeligt funderet fortolkning er denne: Hos kvinder med polycystisk ovariesyndrom og svær overvægt kan normaliseringen af deres metaboliske tilstand ledsages af genoprettelse af ægløsning. Men holdbarheden af denne effekt, strategiens sikkerhed og dens plads i kliniske retningslinjer mangler endnu at blive bekræftet.

Hvad man ved om mænd

Den anden store nyhedsskaber var ENDO 2026, årsmødet i Endocrine Society. Et hold fra University Hospitals Coventry and Warwickshire og Warwick Medical School analyserede publicerede randomiserede forsøg med GLP-1-medicin hos mænd i alderen 18-65 år.

Det systematiske review omfattede fem kliniske forsøg. Forfatterne vurderede testosteronniveauer, sædparametre, kropsvægt, glukose, lipider og overordnet metabolisk sundhed. Data viste ingen konsistent skade på mandlige hormoner, seksuel funktion eller sædkvalitet. Desuden blev der i nogle undersøgelser observeret positive signaler: For eksempel bemærkede et 24-ugers studie med semaglutid forbedringer i sædmorfologi og kolesterolprofil, mens et 16-ugers studie af liraglutid hos mænd med svær overvægt viste en stigning i testosteronniveauet.

Hvorfor dette er biologisk plausibelt

Svær overvægt og insulinresistens kan forstyrre den reproduktive funktion alvorligt hos begge køn. Hos kvinder er de ofte forbundet med uregelmæssig ægløsning og hyperandrogenisme. Hos mænd kan overskydende fedtvæv ledsages af nedsat testosteron, forværrede sædparametre og kronisk systemisk inflammation.

Hvis GLP-1-terapi hjælper med at reducere vægten og forbedre den metaboliske profil, er nogle af de reproduktive ændringer en logisk indirekte konsekvens af denne forbedring. Medicinen "fikser" stofskiftet frem for at virke som en fertilitetsstimulator.

Hvor risikozonen begynder

Den farligste fejl er at forvandle disse tidlige data til hverdagsråd og begynde at injicere GLP-1 "for at blive gravid" eller at fortsætte med at tage medicinen under forsøg på at blive gravid uden at konsultere en specialist.

Den nuværende FDA-indlægsseddel for semaglutid angiver udtrykkeligt, at vægttabsmedicinen bør seponeres mindst 2 måneder før en planlagt graviditet på grund af dens lange udvaskningsperiode fra kroppen. For tirzepatid er der også en streng advarsel: Medicinen kan reducere effekten af orale hormonelle præventionsmidler. Ved start af behandlingen eller ved dosisøgning rådes patienter til midlertidigt at anvende ikke-hormonelle eller barriere-præventionsmetoder.

Der er to sider af dette emne. På den ene side øger forbedret sundhed sandsynligheden for ægløsning. På den anden side kan dette føre til en ikke-planlagt graviditet hos kvinder, der er vant til uregelmæssig menstruation, eller som ikke tager højde for medicinens interaktioner med p-piller.

Hvad man endnu ikke kan hævde

Man kan ikke sige, at GLP-1-medicin helbreder infertilitet. Graviditet kan ikke loves efter et vægttab. Foreløbige data om PCOS kan ikke generaliseres til alle kvinder med reproduktive problemer, og gennemgangen af mænd kan ikke overføres på alle patienter med mandlig infertilitet.

Det er muligt, at disse lægemidler hos nogle mennesker med fedme og stofskiftesygdomme rent faktisk hjælper det reproduktive system til at fungere bedre. Men at indarbejde dette i kliniske protokoller kræver store, langvarige undersøgelser.

Den praktiske konklusion for patienter er enkel: Hvis du tager en GLP-1 og planlægger en graviditet, er i fertilitetsbehandling eller bruger p-piller, skal dette drøftes med en læge. Det er strengt forbudt at ændre behandlingsregimet på egen hånd.

Kilder: CU Anschutz: semaglutide and reproductive outcomes in women with PMOS; CU Anschutz RESTORE Study; Endocrine Society: GLP-1s and male fertility in men with obesity; FDA label: Wegovy / semaglutide; FDA label: Mounjaro / tirzepatid.

De fleste mennesker har hørt om det "dårlige" LDL-kolesterol. Men i de senere år taler kardiologer i stigende grad om en anden markør — lipoprotein(a), eller Lp(a). I modsætning til mange andre risikofaktorer er niveauet heraf i vid udstrækning bestemt af genetik og kan forblive stabilt højt selv hos personer, der opretholder en sund livsstil og spiser rigtigt.

Forhøjet Lp(a) er pålideligt forbundet med en højere risiko for hjerteanfald, slagtilfælde og andre alvorlige kardiovaskulære komplikationer. Mulighederne for at reducere det medicinsk og målrettet i den daglige praksis er dog i øjeblikket alvorligt begrænsede.

Et nyt fase 2 klinisk studie, offentliggjort i det internationale ICH GCP-register under identifikatoren NCT07614984, er dedikeret til netop dette problem. Forskere vil finde ud af, om en kombination af to eksperimentelle orale lægemidler — MK-7262 og enlicitid — effektivt og sikkert kan forbedre kontrollen af den kardiovaskulære risiko hos patienter med høje Lp(a)-niveauer.

Hvorfor Lp(a) tiltrækker sig så meget opmærksomhed

Lp(a) er en særlig type blodlipoprotein. I struktur minder det om en LDL-partikel, men det indeholder et ekstra protein, der kan forstærke åreforkalkningsprocesser, fremme betændelse i karvæggen og øge sandsynligheden for blodpropper.

Det ejendommelige ved Lp(a) er, at niveauet ofte ikke kan korrigeres med kost, motion eller traditionelle statiner. Derfor oplever nogle mennesker alvorlige kardiovaskulære hændelser selv med relativt gunstige resultater på en standard lipidprofil.

Hvad forskerne vil undersøge

Det nye randomiserede studie planlægger at inkludere 750 patienter med et Lp(a)-niveau ≥ 150 nmol/L, som allerede modtager en stabil dosis statiner. Projektet evaluerer en kombination af to tilgange:

• MK-7262: et nyt lægemiddel, der er specifikt udviklet til at sænke Lp(a)-niveauet i blodet.
• Enlicitid (MK-0616): en eksperimentel oral PCSK9-hæmmer, der sigter mod yderligere at reducere det "dårlige" LDL-kolesterol.

Deltagerne vil tilfældigt blive inddelt i grupper, der modtager henholdsvis placebo, MK-7262 alene, enlicitid alene, eller en kombination af begge. Hovedmålet er at vurdere terapiens indvirkning på lipidmetabolisme-markører, samt sikkerhedsprofilen for en sådan behandling over 12 uger.

Hvorfor dette er vigtigt for patienter

Mange mennesker får først kendskab til deres forhøjede Lp(a), når de har oplevet en kardiovaskulær hændelse, eller under specialiserede tests som følge af en familiehistorie med tidlige hjerteanfald.

Interessen for nye metoder til at målrette behandlingen mod denne markør i det videnskabelige samfund er enorm. Hvis studiet bekræfter kombinationens effektivitet, kan det være et stort skridt i retning af nye pillebaserede forebyggende terapier for patienter med en genetisk drevet risiko.

Hvad der forbliver ukendt

På dette stadium er der tale om et fase 2 klinisk studie og ikke en bevist eller godkendt terapi. Det kan endnu ikke hævdes, at kombinationen af MK-7262 og enlicitid er garanteret at reducere risikoen for faktiske hjerteanfald eller slagtilfælde — lægemidlerne skal gennemgå hele cyklussen af kliniske forsøg specifikt for at teste disse hypoteser.

Ikke desto mindre betyder lanceringen af studiet, at en af de mest diskuterede arvelige årsager til kardiovaskulær risiko endelig får en chance for målrettet terapi.

Primær kilde: ClinicalTrials.gov: NCT07614984 (A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a)).
Yderligere kontekst: American Heart Association: Lipoprotein(a).

Illustrativt foto under Unsplash+ licensen

Medicin til behandling af fedme og type 2-diabetes er fortsat et af de mest diskuterede emner inden for medicin. Semaglutid, tirzepatid og andre repræsentanter for GLP-1-klassen (glukagon-lignende peptid-1-receptoragonister) har allerede ændret tilgangen til vægttab for mange patienter. Nu er der opstået et nyt spørgsmål omkring disse lægemidler: Kan de være forbundet med en nedsat risiko for visse kræftformer?

Dette udspringer af flere store studier offentliggjort i de seneste år. Især viste en storskala retrospektiv analyse af elektroniske patientjournaler fra over 1,6 millioner patienter, at personer, der fik medicin af GLP-1-klassen, sjældnere blev diagnosticeret med visse tumorer sammenlignet med dem, der brugte andre tilgange til diabetesbehandling (såsom insulin).

Hvilke kræftformer er der tale om

Forskere er primært interesserede i de såkaldte fedme-associerede tumorer. Disse inkluderer visse tilfælde af lever-, bugspytkirtel-, tarm-, nyre-, æggestokke- og livmoderkræft samt kræft i en række andre organer.

Fedme har længe været anset som en bevist risikofaktor for mere end et dusin typer af ondartede knuder. Derfor er det logisk at antage, at et markant vægttab også kan påvirke onkologiske risici.

Hvad studierne helt præcist viste

Det er vigtigt at forstå, at de fleste af de diskuterede undersøgelser ikke var kliniske forsøg med kræftmedicin. Forskere analyserede eksisterende medicinske journaler og sammenlignede hyppigheden af forskellige diagnoser på tværs af grupper. Lignende observationelle fund er for nylig blevet aktivt diskuteret på store specialiserede konferencer, herunder det årlige møde i American Society of Clinical Oncology (ASCO).

Sådanne resultater gør det muligt at opdage statistiske sammenhænge, men de forklarer ikke altid årsagerne. For eksempel kunne patienter på GLP-1-medicin oprindeligt adskille sig i deres livsstil, sværhedsgraden af følgesygdomme eller kvaliteten af den medicinske overvågning.

Er en direkte anti-tumor effekt mulig?

Der er endnu intet endeligt svar på dette spørgsmål. Nogle forskere foreslår, at virkningen muligvis ikke kun er forbundet med selve vægttabet, men også med ændringer i stofskiftet, en reduktion i systemisk inflammation og normalisering af insulinniveauer.

Disse mekanismer forbliver dog et emne for grundforskning. Til dato er der ingen beviser for, at GLP-1-lægemidler har en direkte tumorhæmmende effekt og bør ordineres specifikt til forebyggelse af kræft.

Hvad patienter skal huske

På nuværende tidspunkt er medicin i GLP-1-klassen godkendt af tilsynsmyndigheder strengt til behandling af type 2-diabetes og fedme (eller overvægt med tilknyttede risici) under fastsatte indikationer. De er ikke registreret som midler til kræftforebyggelse.

Derfor bør disse nye studier indtil videre betragtes som en vigtig videnskabelig retning og ikke som et bevis på, at vægttabsmedicin garanteret beskytter mod kræft.

Primær kilde: JAMA Network Open: Risk of 13 Obesity-Associated Cancers Among Patients With Type 2 Diabetes Treated With Glucagon-Like Peptide-1 Receptor Agonists.
Yderligere kontekst: National Cancer Institute: Obesity and Cancer.

 Illustrativt foto af Unsplash+ License

Atrieflimmer er en af de mest almindelige hjerterytmeforstyrrelser. Ved denne tilstand kan der dannes blodpropper i hjertet, som derefter rejser gennem blodbanen til hjernens kar og forårsager et iskæmisk slagtilfælde.

For at reducere denne risiko får patienter ordineret antikoagulantia — medicin, der nedsætter blodets størkningsevne. Men for nogle mennesker er dette valg særligt svært: nemlig for patienter, der allerede har lidt en spontan intracerebral blødning (hjerneblødning) i fortiden.

I en sådan situation er en læge tvunget til at balancere mellem to alvorlige trusler. På den ene side stiger risikoen for et nyt iskæmisk slagtilfælde uden blodfortyndende medicin. På den anden side øger brugen af blødende medicin kritisk risikoen for tilbagevendende, ofte alvorlige blødninger.

Det er præcis dette kliniske dilemma, det nye multicenter randomiserede studie OASIS-AF vil undersøge. Fase 4-protokollen er offentliggjort i det internationale ICH GCP-register under identifikatoren NCT07609654.

Hvem der vil blive inkluderet i studiet

OASIS-AF planlægger at indskrive 852 voksne patienter. Udvælgelseskriterierne er strenge: Deltagerne skal have bekræftet ikke-valvulær atrieflimmer, de skal have haft et akut iskæmisk slagtilfælde, og deres sygehistorie skal allerede indeholde en registreret spontan intracerebral blødning.

Dette er en specifik patientgruppe, for hvem standardprotokoller til forebyggelse af slagtilfælde ikke fungerer så ligetil. Patienten befinder sig samtidig i en højrisikozone for alvorlige tromboemboliske komplikationer og i en ekstremrisikozone for farlige blødninger.

Hvad der vil blive sammenlignet

Deltagerne vil blive tilfældigt fordelt i to grupper. I den første gruppe vil patienterne få ordineret direkte orale antikoagulantia (DOAK'er) — moderne medicin, som i øjeblikket er standarden for forebyggelse af slagtilfælde ved atrieflimmer.

I den anden gruppe vil orale antikoagulantia ikke blive brugt. Beslutningen om yderligere taktik vil forblive hos den behandlende læge: Patienten kan få ordineret blodpladehæmmende behandling (f.eks. aspirin) eller blive håndteret helt uden antitrombotisk behandling.

Hvilket spørgsmål forskerne forsøger at besvare

Hovedspørgsmålet for OASIS-AF er ikke, om blodfortyndende medicin virker i princippet — deres beskyttende rolle ved atrieflimmer har længe været bevist. Spørgsmålet er meget mere komplekst: Er deres brug retfærdiggjort hos dem, hvis hjernekar allerede har vist sig at være sårbare over for bristninger?

Lægerne vil evaluere hyppigheden af tilbagevendende slagtilfælde (både iskæmiske og hæmoragiske). Tilfælde af vaskulær død, samlet dødelighed og eventuelle større blødninger vil også blive nøje overvåget.

Hvorfor dette er vigtigt for patienter og læger

Hvis studiet viser, at antikoagulationsbehandling giver et bedre samlet klinisk resultat uden en uacceptabel stigning i alvorlige blødninger, vil det hjælpe neurologer og kardiologer med at ordinere beskyttelse til patienter i denne komplekse gruppe med større selvtillid.

Hvis risikoen for tilbagevendende hjerneblødning derimod opvejer de forventede fordele, vil dette blive et stærkt argument for en mere forsigtig strategi og søgen efter alternative forebyggelsesmetoder.

Hvad der endnu ikke kan hævdes

Det er vigtigt at forstå, at OASIS-AF endnu ikke giver svar på disse spørgsmål. Studiets profil angiver en status som not yet recruiting, hvilket betyder, at rekrutteringen af deltagere endnu ikke er startet.

Derfor kan det ikke hævdes på nuværende tidspunkt, at blodfortyndende medicin allerede har bevist deres sikkerhed eller ubetingede fordel for alle patienter med atrieflimmer efter en hjerneblødning. Essensen af nyheden ligger et andet sted: Lægestanden igangsætter en højkvalitetsundersøgelse af et af de mest komplekse "gråzoner" inden for vaskulær neurologi.

Primær kilde: ClinicalTrials.gov: NCT07609654 (OASIS-AF).
Yderligere kontekst: American Stroke Association: sammenhængen mellem atrieflimmer og risiko for slagtilfælde; European Society of Cardiology: kliniske retningslinjer for håndtering af patienter med atrieflimmer; Stroke (AHA Journals): forskning i dilemmaet omkring ordinering af antikoagulantia efter intracerebral blødning.

Spencer Davis / Unsplash

Kunstig intelligens bruges i stigende grad inden for lægemiddeludvikling, men indtil for nylig var der næsten ingen af disse eksempler inden for vaccinologi. Nu har forskere i Storbritannien rapporteret resultaterne fra de første forsøg på mennesker med en eksperimentel vaccine mod en gruppe af coronavirus, designet ved hjælp af kunstig intelligens.

Resultaterne af undersøgelsen blev offentliggjort i Journal of Infection.

Hvad er dette for en vaccine?

Der er tale om vaccinen pEVAC-PS, udviklet af forskere ved Cambridge University i samarbejde med biotekvirksomheden DIOSynVax.

I modsætning til de eksisterende COVID-19-vacciner, som blev skabt mod en specifik variant af SARS-CoV-2, er det nye lægemiddel tænkt som en potentiel beskyttelse mod en hel familie af sarbecovirus – en gruppe af coronavirus, der inkluderer SARS-CoV, SARS-CoV-2 og flere virusser, der cirkulerer blandt flagermus.

For at udvælge de dele af virussen, der kan udløse det bredeste immunrespons, brugte forskerne AI-algoritmer og beregningsmæssige modelleringsmetoder.

Hvordan forløb undersøgelsen?

Forsøget var et fase 1 klinisk studie, hvis primære formål er at vurdere lægemidlets sikkerhed.

Undersøgelsen involvererede 39 raske voksne frivillige i Storbritannien, som tidligere var blevet vaccineret mod COVID-19. Deltagerne modtog forskellige doser af den eksperimentelle vaccine, hvorefter forskerne overvågede dem for mulige bivirkninger og vurderede deres immunrespons.

Hvad var resultaterne?

Ifølge de offentliggjorte data blev der ikke rapporteret om alvorlige vaccinerelevante bivirkninger. De mest almindelige reaktioner var smerter på injektionsstedet, træthed, hovedpine og kortvarigt ubehag.

De fleste bivirkninger var milde eller moderate. Derudover rapporterede forskerne om dannelsen af et immunrespons mod flere medlemmer af sarbecovirus-familien. Ifølge forfatterne kan dette indikere et potentiale for at skabe mere universelle vacciner mod coronavirus.

Hvorfor dette ikke betyder en ny vaccine lige foreløbig

På trods af store overskrifter om "den første AI-skabte vaccine", bør resultaterne fortolkes med forsigtighed.

Fase 1-forsøg gør det muligt at vurdere lægemidlets sikkerhed og indsamle foreløbige data om immunogenicitet, men de viser ikke, hvor godt vaccinen reelt beskytter mennesker mod sygdommen. At besvare dette spørgsmål vil kræve meget større fase 2- og fase 3-forsøg med et betydeligt større antal frivillige. Derudover inkluderede forsøget kun 39 personer, hvilket gør det for tidligt at drage vidtrækkende konklusioner.

Hvad dette kan betyde for medicinen

Den største nyhed ligger ikke så meget i selve vaccinen, men i tilgangen til dens udvikling.

Hvis brugen af kunstig intelligens virkelig kan hjælpe forskere med at finde lovende antigener hurtigere og skabe medicin mod hele grupper af virusser, kan det fremskynde vores beredskab til fremtidige pandemier. Dette er dog i øjeblikket kun en tidlig forskningsfase. Forskerne skal stadig bekræfte, at det AI-designede lægemiddel er i stand til at give reel beskyttelse i store kliniske forsøg.

Primær kilde:ISRCTN: the UK's Clinical Study Registry, Health Research Authority, Journal of Infection. Yderligere kontekst: Cambridge University, DIOSynVax.

Illustrativt foto af Testalize.me / Unsplash

Blod i urinen er et symptom, der er svært at ignorere. Nogle gange er det umiddelbart synligt, mens det andre gange kun opdages ved en laboratorieanalyse. Årsagerne kan variere meget, fra infektioner og sten til betændelse eller nyresygdom. Men en diagnose, som lægerne definitivt skal udelukke, er urotelialt karcinom, som omfatter tumorer i blæren og de øvre urinveje.

Den diagnostiske vej i sådanne situationer fører ofte til en cystoskopi, billeddiagnostik og, hvis der findes en mistænkelig masse, vævsprøvetagning. Selvom dette giver afgørende klinisk information, kan forløbet være ubehageligt, angstprovokerende og meget invasivt for patienten.

Et nyt studie offentliggjort i ICH GCP-registret under identifikator NCT07614594 vil evaluere en ikke-invasiv urintest designet til at opdage urotelialt karcinom. Forskningen er struktureret som et totrins prospektivt observationsstudie med strengt fokus på diagnostisk nøjagtighed.

Hvem vil blive inkluderet

Forsøget planlægger at indskrive 800 voksne patienter. For at deltage skal individer have enten makroskopisk (synlig) hæmaturi eller mikrohæmaturi samt billeddiagnostiske data, der viser en masse i nyrebækkenet, urinlederen eller blæren.

En anden streng betingelse er, at patienten allerede skal være planlagt til en diagnostisk cystoskopi og/eller kirurgisk vævsindsamling. Dette er en kritisk skelnen: Urintesten bliver ikke undersøgt hos tilfældige raske individer eller som et massescreeningsværktøj. Den testes specifikt på patienter, der allerede navigerer i et diagnostisk forløb for en mistænkt tumor.

Hvad bliver sammenlignet?

Forskere vil indsamle urinprøver fra deltagerne til laboratorieanalyse. Resultaterne af denne ikke-invasive test vil derefter blive krydsrefereret med referencestandarden – en histopatologisk rapport, hvilket betyder en mikroskopisk undersøgelse af det biopterede væv.

De primære parametre for studiet er sensitivitet og specificitet. Sensitivitet indikerer, hvor godt testen identificerer kræft blandt dem, der rent faktisk har det. Specificitet omhandler den anden side: hvor godt testen undgår at udløse en falsk alarm hos personer uden en tumor.

Hvorfor urologer er interesserede i urintest

Urotelialt karcinom udvikler sig fra slimhinden i urinvejene. På grund af dette er den underliggende logik i en urintest ligetil: tumorceller, DNA eller andre molekylære spor kan frigives til urinen og tjene som lettilgængeligt diagnostisk materiale.

I praksis er biologien dog meget mere kompleks. Forskellige tumorer opfører sig forskelligt; tidlige og lavgradige former producerer muligvis kun et svagt signal, mens inflammation eller andre godartede sygdomme i urinvejene nemt kan forstyrre fortolkningen. Derfor skal en ny test bevise, ikke blot at den er et smart laboratoriekoncept, men at den fungerer pålideligt i en virkelig klinisk population.

Cystoskopi er fortsat et nøgletrin

National Cancer Institute (NCI) beskriver en cystoskopi som en procedure, hvor en læge undersøger indersiden af blæren og urinrøret og om nødvendigt tager vævsprøver. På nuværende tidspunkt er det netop disse direkte visualiserings- og biopsimetoder, der muliggør en bekræftet diagnose og korrekt tumorevaluering.

På grund af dette vil selv en meget vellykket urintest ikke automatisk betyde afslutningen på cystoskopier eller biopsier. En mere realistisk fremtidig rolle for sådanne tests er at hjælpe med at vurdere risikoen præcist, supplere den diagnostiske standardrute og potentielt reducere unødvendige invasive procedurer for en undergruppe af patienter. Men dette potentiale kræver solide beviser.

Hvad der endnu ikke kan hævdes

På dette tidspunkt kan det ikke hævdes, at denne nye urintest opdager kræft i blæren eller de øvre urinveje med tilstrækkelig nøjagtighed til at erstatte eksisterende klinisk diagnostik. Patienter kan heller ikke loves, at aflevering af en enkelt urinprøve vil skåne dem for at gennemgå en cystoskopi.

Formålet med studiet er mere afmålt og praktisk: at verificere, hvor godt en ikke-invasiv urintest stemmer overens med de definitive resultater af standard histologi hos personer, der allerede har en stærk klinisk mistanke om urotelialt karcinom.

Primær kilde: ICH GCP: NCT07614594.
Yderligere kontekst: American Cancer Society; NCI; AUA/SUFU Guideline.

Et af de vanskeligste øjeblikke i svangreomsorgen opstår, når en ultralyd eller en MR-scanning afslører en strukturel anomali hos fosteret, men standard genetiske test ikke kan forklare, hvorfor det skete. For de kommende forældre medfører denne diagnostiske blindgyde ikke kun enorm angst, men også en dyb usikkerhed med hensyn til prognosen, den neonatale pleje og risikoen for gentagelse ved fremtidige graviditeter.

Et nyt multicenterstudie i Kina retter sig mod netop denne diagnostiske blinde plet. Forsøget er registreret i ICH GCP-databasen under identifikatoren NCT07606989 og er sponsoreret af Women’s Hospital School of Medicine Zhejiang University.

Hvad der præcist bliver undersøgt

Forskningen fokuserer på helgenomsekventering (WGS). I modsætning til målrettede tests, der kun ser på specifikke kromosomale ændringer eller de proteinkodende regioner af gener, analyserer WGS hele genomet. På grund af dette brede omfang har det potentiale til at opdage typer af varianter, der rutinemæssigt glider igennem standard diagnostiske veje.

Studiet planlægger at indskrive 1.000 kvinder med enkeltfoldsgraviditeter. For at kvalificere sig skal en strukturel anomali være påvist på en føtal ultralyd eller MR-scanning mellem 11+0 og 32+0 svangerskabsuger. Afgørende er det, at standard genetisk testning – herunder karyotypering, kromosomal microarray (CMA), CNV-seq, hel-exom sekventering (WES) eller målrettede genpaneler – allerede har fejlet i at give en forklaring.

Hvorfor standardtests nogle gange ikke er nok

Karyotypering er yderst effektiv til at identificere store kromosomafvigelser. Kromosomal microarray og CNV-seq udmærker sig ved at finde mindre manglende eller duplikerede strækninger af DNA. Hel-exom sekventering scanner primært de kodende regioner af gener, hvor en betydelig del af kendte sygdomsfremkaldende varianter er placeret.

Genetikken bag strukturelle føtale anomalier er dog sjældent enkel. Den grundlæggende årsag kan ligge i komplekse strukturelle varianter, bittesmå ændringer, ikke-kodende regioner, regulatoriske elementer, mosaik eller en kombination af faktorer. WGS løser ikke automatisk alle disse puslespil, men det giver et meget bredere net af data, som genetikerne kan analysere.

Hvad forskerne håber at opnå

Det primære endepunkt for forsøget er det diagnostiske udbytte af WGS: procentdelen af tidligere uforklarlige tilfælde, hvor helgenomsekventering med succes identificerer en patogen eller sandsynlig patogen variant, der er ansvarlig for anomalien. Forskerne vil også sammenligne dette diagnostiske udbytte direkte med det nuværende standardforløb.

Et kritisk sekundært fokus er varianter af usikker signifikans (VUS). Dette er et af de mest følsomme områder inden for genomisk medicin: en genetisk ændring findes, men dens kliniske indvirkning er i øjeblikket ukendt. Protokollen angiver, at forskerne vil spore omklassificeringsraten – hvor mange af disse usikre varianter, der med tiden kan flyttes til en klarere kategori, efterhånden som yderligere data bliver tilgængelige.

Hvorfor dette er vigtigt for familier

En definitiv genetisk diagnose kan ændre hele landskabet for en graviditet. Det former prognosen, justerer den prænatale håndteringsplan, forbereder det medicinske team på specialiseret neonatal pleje og giver vital information vedrørende risikoen for gentagelse og genetisk rådgivning til udvidede familiemedlemmer.

Alligevel er svarene ikke altid ligetil. Nogle gange finder WGS ingenting. Andre gange afdækker det en variant, hvis betydning ikke med sikkerhed kan forklares. Af og til afslører det sekundære fund, der påvirker forældrenes eget helbred. På grund af dette kræver avanceret diagnostik ikke kun sofistikeret sekventeringsteknologi, men yderst kompetent og empatisk genetisk rådgivning.

Ikke en test for alle graviditeter

Det er vigtigt ikke at forveksle denne specialiserede forskning med rutinemæssig prænatal screening. Dette studie er rettet mod en meget specifik klinisk gruppe: graviditeter, hvor strukturelle anomalier allerede er blevet opdaget, og invasive eller postnatale diagnostiske procedurer allerede er planlagt.

Desuden er WGS ikke designet til at erstatte ultralyd, MR-scanninger, konsultationer med specialister i føtalmedicin eller grundlæggende genetiske test. I stedet evalueres det som et ultimativt supplerende undersøgelsesniveau for tilfælde, der forbliver uløste.

Hvad der fortsat er ubevist

Det kan ikke antages, at WGS automatisk vil finde årsagen til enhver anomali eller i sig selv forbedre graviditetsudfaldene. Det er også for tidligt at love, at bredere genomisk sekventering altid vil give handlingsorienterede svar. Jo flere data der genereres, jo større er byrden med fortolkning, klinisk validering og omhyggelig kommunikation med familien.

Primær kilde: ICH GCP: NCT07606989.
Yderligere kontekst: American Journal of Obstetrics and Gynecology; AJOG; ACMG.

Medicinsk infografik

Kronisk pancreatitis er mere end blot tilbagevendende mavesmerter eller fordøjelsesproblemer. Det er en tilstand af langvarig inflammation, der fundamentalt kan ændre bugspytkirtlens væv over årtier. For en undergruppe af disse patienter øger dette miljø risikoen for at udvikle kræft i bugspytkirtlen, men det er stadig en stor medicinsk udfordring at afgøre, hvem der præcist har den højeste risiko.

Et nyt projekt på Changhai Hospital er dedikeret til at tackle denne diagnostiske usikkerhed. Studiet, der er registreret i ICH GCP-databasen under identifikatoren NCT07612566, fokuserer på at "afkode immunrepertoiret" – en analyse af, hvordan immuncellernes sammensætning og adfærd ændrer sig under kronisk pancreatitis og kræft i bugspytkirtlen.

Hvad forskerne leder efter

Forskerne tester ikke et nyt lægemiddel eller tilbyder en køreklart screeningstest. I stedet vil de observere tre forskellige grupper: raske frivillige, personer med kronisk pancreatitis og patienter, der for nylig har fået diagnosticeret duktalt adenokarcinom i bugspytkirtlen (PDAC).

Deltagerne vil levere blodprøver og kliniske data. For nogle patienter vil vævsprøver, hvis de er tilgængelige gennem standard medicinsk behandling, også blive analyseret. I blodet vil forskerne specifikt undersøge T-celle- og B-cellereceptor-repertoiret – og i bund og grund læse signaturerne af, hvordan immunsystemet genkender og sporer trusler.

Hvorfor immunsystemet betyder noget

Kræft opstår ikke i et vakuum. En tumor forudgås ofte af årtiers inflammation, vævsskade, forsøg på strukturel reparation og konstant interaktion mellem immunceller og det omskiftelige miljø omkring bugspytkirtelgangene.

Aktuelle anmeldelser af kronisk pancreatitis og bugspytkirtelkræft fremhæver immunceller som en kritisk del af dette mikromiljø. De spiller en rolle i den inflammation, fibrose og de cellulære ændringer, der ledsager sygdommens progression. At omsætte denne biologiske viden til et klart, handlingsorienteret risikovurderingsværktøj er dog komplekst.

Hvordan observationen er struktureret

Ifølge ICH GCP-registret planlægger forsøget at indskrive 800 deltagere. Dem med kronisk pancreatitis vil blive overvåget nøje med opfølgninger planlagt cirka hver 6. til 12. måned. Forskerne vil krydsreferere immunmarkørerne med CT- eller MR-scanning, rutinemæssige laboratorietests, genetiske data og patientens overordnede kliniske billede.

Et dedikeret mål med studiet er at udvikle og validere en AI-baseret risikostratificeringsmodel. Sagt mere enkelt er målet at bygge en beregningsmodel, der er i stand til at syntetisere forskellige datatyper for at lokalisere, hvilke patienter med kronisk pancreatitis, der har større sandsynlighed for at udvikle kræft i bugspytkirtlen.

Potentielle fordele for patienter

Kræft i bugspytkirtlen er berygtet for at være svær at opdage tidligt. På grund af dette har læger desperat brug for bedre måder at triagere patienter til overvågning – for at undgå unødig angst og procedurer for alle, samtidig med at man sikrer, at de, der virkelig har brug for omhyggelig diagnostisk billeddannelse, ikke falder igennem sprækkerne.

Opretholdelse af et forsigtigt perspektiv

Det kan endnu ikke påstås, at en blod-immunprofiltest allerede kan forudsige kræft i bugspytkirtlen. Det er lige så vigtigt ikke at præsentere den foreslåede AI-model som et færdigt diagnostisk værktøj. Forsøget er endnu ikke begyndt at rekruttere deltagere; den officielle status er "not yet recruiting", med dataindsamling og observation planlagt til at løbe til udgangen af 2028.

Primær kilde: ICH GCP: NCT07612566.
Yderligere kontekst: American Cancer Society; Cancers; Frontiers in Oncology.

Surviving a heart attack, an episode of acute heart failure, or a severe arrhythmia is only the first step. When a patient is discharged, they are usually handed a long list of instructions: new medications, blood pressure tracking, dietary limits, and follow-up appointments. In the midst of all this, getting a seasonal flu shot might seem like a minor detail. However, for cardiovascular patients, avoiding the flu is a critical piece of the survival puzzle.

Wroclaw Medical University is launching a clinical trial to change when and how these vulnerable patients get vaccinated. Instead of telling them to do it later, doctors will offer the shot right before they leave the hospital. The study is registered in international databases under the identifier NCT07617376.

Closing the Prevention Gap

Currently, the standard medical workflow involves advising a hospitalized heart patient to visit their primary care physician for a flu shot after discharge. Unfortunately, reality often gets in the way. Patients are exhausted from their hospital stay, overwhelmed by new medications, or simply don't view the vaccine as an urgent priority. This creates a dangerous gap in care.

The new trial aims to eliminate this gap entirely. Patients in the experimental group will receive a seasonal influenza vaccine within 24 hours prior to their discharge. The control group will receive standard care, which includes a verbal or written recommendation to get vaccinated at an outpatient clinic later.

Who is Participating?

This is a single-center, randomized, open-label Phase 4 trial. Researchers plan to enroll 400 adult patients hospitalized for acute cardiac conditions, including myocardial infarction (heart attack), acute or decompensated heart failure, pulmonary embolism, severe arrhythmias, and hypertensive emergencies.

To be eligible, participants must be ready to go home within the next 48 hours and must not have received a flu shot during the current season. Those with a history of severe vaccine reactions or who are being transferred to another hospital or long-term care facility are excluded from the study.

Measuring What Really Matters

The study’s primary endpoint is a composite measure that tracks infections, unplanned cardiovascular hospitalizations, and cardiovascular deaths over the six months following discharge.

This makes the trial highly practical. Researchers aren’t just trying to see if they can boost vaccination statistics; they want to know if this specific timing actually alters the course of the patient's recovery and reduces the burden on the healthcare system.

Why the Flu is So Dangerous for the Heart

For a healthy adult, the flu means a fever, a cough, and a few days in bed. For someone with a compromised cardiovascular system, it acts as a massive stressor. The virus spikes inflammation, drastically increases the body's demand for oxygen, and can trigger arrhythmias or decompensate chronic conditions.

The CDC explicitly warns that people with heart disease or a history of stroke face a significantly higher risk of severe flu complications. Conversely, vaccination has been associated with a lower rate of adverse cardiac events, especially in patients who have suffered a heart emergency within the past year.

Why We Still Need to Test It

The concept sounds like common sense: if a high-risk patient is already in a hospital bed, give them the vaccine before they leave. However, in medicine, even simple logistical shifts require rigorous proof. Doctors need concrete data to ensure this pre-discharge workflow is safe, doesn't interfere with acute treatments, and genuinely improves long-term outcomes.

It is important to note that a pre-discharge flu shot is not a magical cure or a replacement for cardiac therapy. This trial is simply investigating whether a smarter, more timely approach to a well-known preventive measure can provide an extra layer of protection when patients need it most.

 Robina Weermeijer on Unsplash

High LDL cholesterol remains one of the primary targets in preventing heart attacks and strokes. While statins are the cornerstone of lipid-lowering therapy, a significant number of patients fail to reach their target LDL-C levels even on the highest tolerable doses. In such cases, cardiologists must consider add-on therapies.

This clinical challenge is the focus of a newly launched trial named MEDICI. Registered on ClinicalTrials.gov under the identifier NCT07614958, the study is being conducted by A. Menarini International Licensing S.A. in collaboration with Medpace.

Two Drugs, Different Mechanisms

The MEDICI trial will conduct a head-to-head comparison of obicetrapib and bempedoic acid. Both are once-daily oral medications, but they operate through entirely different biochemical pathways.

Obicetrapib is an experimental CETP inhibitor. CETP is a protein involved in the transfer of cholesterol between lipoproteins. Blocking it is being evaluated as a method to lower LDL-C and influence other lipid parameters. The medical community is observing obicetrapib closely, as earlier drugs in the CETP inhibitor class historically failed to meet clinical expectations.

Bempedoic acid, conversely, is an already approved non-statin drug. It acts on the same cholesterol-synthesis pathway as statins but does so primarily within the liver. This makes it a frequently discussed option for patients who need additional LDL-C reduction or those who struggle with statin tolerance.

How the MEDICI Trial is Designed

MEDICI is a randomized, double-blind, active-controlled Phase 3 study aiming to enroll 426 adult participants. These patients must have primary non-familial hypercholesterolemia or mixed dyslipidemia, alongside a high or very high cardiovascular risk profile.

A crucial inclusion criterion is that participants must have elevated LDL-C despite being on stable, maximally tolerated lipid-lowering therapy. This background therapy usually involves the maximum tolerated statin dose and may also include ezetimibe or a PCSK9 inhibitor.

Participants will be randomly assigned to receive either 10 mg of obicetrapib plus a bempedoic acid placebo, or 180 mg of bempedoic acid plus an obicetrapib placebo. The primary endpoint is the percentage change in LDL-C from baseline to day 84.

Why a Direct Comparison is Crucial

Many clinical trials test new lipid-lowering drugs against a placebo. While that design proves whether a drug works compared to doing nothing, it leaves practical medical questions unanswered. For a practicing doctor, the most critical question is: how does this new option compare to the alternative I already have?

By placing obicetrapib directly against bempedoic acid, MEDICI aims to provide real-world value. It moves beyond theoretical lab effects to offer a direct comparison between two non-statin oral strategies for high-risk patients.

Looking Beyond Just LDL-C

In addition to the primary endpoint, researchers will evaluate changes in non-HDL-C, HDL-C, ApoA1, ApoB, triglycerides, and Lp(a). This comprehensive approach is vital because cardiovascular risk is driven by more than just a single LDL-C number, even though LDL-C remains the primary therapeutic target.

However, it is important to note that a 12-week timeframe is only sufficient for evaluating lipid markers. It is not long enough to determine if the drug ultimately reduces the actual occurrence of heart attacks, strokes, or cardiovascular deaths. Such conclusions require much longer, dedicated outcome trials.

What Remains Unproven

The launch of MEDICI does not preemptively prove that obicetrapib is superior, safer, or more clinically beneficial than bempedoic acid. The trial must first collect robust data regarding the reduction of LDL-C, other lipid markers, and overall patient tolerability.

The significance of this news lies in the intensifying development of non-statin oral options. For patients struggling to control their cholesterol despite high cardiovascular risk, this direct comparison could eventually help refine standard treatment guidelines.

When treating advanced prostate cancer, oncologists are increasingly moving beyond traditional hormone therapy and chemotherapy. Modern approaches often seek out tumor cells using molecular "tags." One of the most prominent targets is PSMA—a protein frequently found in large quantities on the surface of prostate cancer cells.

AstraZeneca is now launching the VECTRA-01 clinical trial to test a new drug called AZD2265 (also known as FPI-2265 or ²²⁵Ac-PSMA-I&T). The study is registered on clinicaltrials.gov under the identifier NCT07611110.

The Concept Behind the Treatment

AZD2265 belongs to a class of treatments known as PSMA-targeted radioligand therapies. In simple terms, this therapy acts like a guided delivery system: one part of the molecule seeks out and binds to PSMA-positive cells, while the other part delivers a radioactive payload designed to damage the tumor cell upon binding.

In the case of AZD2265, the payload is Actinium-225, an alpha-emitting radioisotope. Alpha therapy is particularly interesting to scientists because its radiation travels a very short distance. Theoretically, this allows for highly precise destruction of tumor cells while sparing surrounding healthy tissue, but its actual safety and clinical benefit must be strictly proven in trials.

Who is Eligible for the Trial?

The study focuses on men with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). This is an advanced stage where the disease has spread beyond the prostate gland and continues to progress despite low testosterone levels or ongoing androgen deprivation therapy.

According to the trial protocol, participants must have previously undergone at least one taxane-based chemotherapy regimen and at least one androgen receptor pathway inhibitor (such as enzalutamide or abiraterone). A positive PSMA PET/CT scan is also required for inclusion.

What is AZD2265 Compared Against?

VECTRA-01 is an international, randomized Phase 3 trial planning to enroll 670 participants. AZD2265 will be directly compared to standard-of-care therapies chosen by the investigator. Options include cabazitaxel, abiraterone, enzalutamide, apalutamide, darolutamide, rezvilutamide, and radium-223.

The primary endpoints are radiographic progression-free survival (rPFS) and overall survival (OS). This means researchers are looking not only at tumor scans, but at the most critical clinical question: does this therapy help patients live longer?

Why This Trial Matters

PSMA-targeted radioligand therapy has already become a major breakthrough in late-stage prostate cancer. For instance, the FDA previously expanded the indication for Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for certain patients with PSMA-positive mCRPC.

However, AZD2265 is a fundamentally different drug. It utilizes a different delivery molecule and a different radioactive isotope (actinium instead of lutetium). Therefore, the success of existing PSMA-targeted therapies does not guarantee that this new drug will automatically be effective or safe.

Why Caution is Necessary

Phrases like "targeted radiation therapy" sound powerful, but they should not be mistaken for a guaranteed cure. Even when a drug targets PSMA, tumors can be highly heterogeneous—meaning different metastatic spots might absorb the radioligand differently. Additionally, managing potential side effects remains a critical part of the medical evaluation.

At this stage, it cannot be claimed that AZD2265 outperforms standard therapies, extends overall survival, or slows disease progression. The VECTRA-01 trial is designed exactly to answer those questions.

The core news here is the advancement of a new Phase 3 trial, pushing the boundaries of radioligand therapy for a vulnerable group of patients who have already exhausted multiple lines of standard treatment.

In real life, however, many patients arrive at the hospital past the classic window for intravenous thrombolysis. Some wake up with symptoms, some are alone at home, and others do not immediately realize that arm weakness, facial drooping, or slurred speech could indicate a stroke.

A new clinical trial is launching in China to test a simpler approach to selecting these late-arriving patients. The study, named PEARL-SIMPLIFIED, is registered on ICH GCP under the identifier NCT07606807.

What exactly will be tested?

PEARL-SIMPLIFIED is a multicenter, randomized controlled, open-label, blinded-endpoint Phase 3 trial. The study plans to enroll 750 adult patients suffering from an acute anterior circulation ischemic stroke.

• The critical factor is the time window: participants must be admitted between 4.5 and 24 hours from symptom onset or from the time they were last known to be well.
• This inclusion covers "wake-up strokes" and strokes with an undetermined exact time of onset.
• Patients will be selected using simplified criteria based solely on a non-contrast CT scan.
• Participants will be randomly assigned into two groups: one receiving intravenous tenecteplase, and the other receiving standard medical therapy.

Why a simple CT scan is a game-changer

In the extended time window, doctors typically need to determine if there is still salvageable brain tissue and assess the risk of hemorrhage. To do this, many current protocols rely on advanced imaging techniques like CT perfusion or MRI.

However, these advanced technologies are not available in every hospital, particularly in smaller centers or resource-limited regions. A standard non-contrast CT is much faster and more widely accessible. If it proves safe to select certain patients for treatment using only a basic CT, it could revolutionize stroke care in areas lacking advanced imaging infrastructure.

What we know about tenecteplase

Tenecteplase is a thrombolytic (clot-busting) drug. The 2026 update from the AHA/ASA supports intravenous thrombolysis within 4.5 hours for eligible patients. The guidelines also recognize tenecteplase as a viable alternative to alteplase within this standard window.

Recently, JAMA published data regarding tenecteplase use in the 4.5–24 hour window, but patient selection in that context relied on perfusion imaging. The PEARL-SIMPLIFIED trial distinguishes itself by testing this treatment based exclusively on simple non-contrast CT screening.

What we cannot claim yet

It is premature to claim that tenecteplase is safe and effective for all stroke patients in the 4.5–24 hour window. Likewise, it cannot be asserted that a standard CT scan is already a proven substitute for advanced imaging in these late-stage medical decisions.

The trial will rigorously evaluate functional outcomes and safety profiles, as thrombolysis inherently carries bleeding risks. PEARL-SIMPLIFIED aims to determine whether late thrombolysis patient selection can be simplified, but standard clinical practice will not change until the Phase 3 results are published and peer-reviewed.

Huntington's disease is a rare, devastating inherited brain disorder that gradually and relentlessly strips away a person's control over their body and mind. The disease severely impacts movement, cognition, behavior, and the ability to live independently. It is an especially heavy diagnosis for families to bear, as it is caused by a mutation in the HTT gene and frequently affects multiple generations.

Given the desperate need for treatments that can slow the progression of the disease, the launch of a new clinical trial for the drug pridopidine has captured the medical community's attention. The trial is registered in the international database under the identifier NCT07609108, sponsored by Prilenia in collaboration with Ferrer Internacional S.A.

What exactly will doctors be testing?

This is a large-scale, randomized, double-blind, placebo-controlled Phase 3 clinical trial. According to the registry, researchers plan to enroll 400 adult participants with confirmed Huntington's disease.

During the first year, participants will take either pridopidine or a placebo twice a daily. This will be followed by a two-year open-label extension period, during which all eligible participants will have the option to receive the actual drug so researchers can assess its long-term effects.

The primary goal of the study is to measure changes in the composite Unified Huntington’s Disease Rating Scale (cUHDRS) by week 52. This comprehensive scale combines several critical aspects of the disease: daily functional independence, motor function, information processing speed, and cognitive flexibility.

Why is this study different from the last one?

Pridopidine previously underwent a major trial known as PROOF-HD. The results were mixed: the drug failed to meet its primary and key secondary endpoints in the overall patient population. However, researchers noted a favorable safety profile and clear signals of potential benefit in a specific subgroup of participants—those who were not taking antidopaminergic medications.

The new trial is built directly upon those findings. The protocol for NCT07609108 strictly requires that participants must not have used these specific medications (including VMAT2 inhibitors and neuroleptics/antipsychotics) for at least 6 months prior to screening. However, the protocol explicitly highlights a crucial ethical guideline: patients are strongly advised against stopping necessary, currently prescribed treatments simply to qualify for this trial.

Why this matters so much to patients

Current treatments for Huntington's disease are almost entirely symptomatic. Doctors can prescribe medications to help manage involuntary movements (chorea), sleep disturbances, or psychiatric symptoms. However, there is still no approved therapy that reliably halts the destruction of neurons and slows the clinical progression of the disease itself.

Because of this, the new Phase 3 trial is not viewed as a "second attempt at any cost," but rather as a highly targeted scientific hypothesis. Researchers want to determine whether pridopidine can deliver a meaningful effect for a specific group of patients when evaluated against a comprehensive measure of functional decline.

What we don't know yet

At this stage, researchers do not claim that pridopidine demonstrably slows Huntington's disease, improves coordination, preserves memory, or extends independent living. The study is slated to begin in June 2026 and is not yet recruiting participants.

The accurate takeaway is this: following a complex previous trial, scientists are relaunching their investigation into the drug with a much more focused approach. For families facing Huntington's disease, this represents an important ray of hope and a critical scientific endeavor, but it is not yet a proven clinical solution.

Primary source: ICH GCP: NCT07609108.
Additional context: Nature Medicine: PROOF-HD phase 3 trial; NINDS: Huntington’s disease; MedlinePlus Genetics: Huntington disease.

Photo by RAJA IMRAN BAHADR on Unsplash

Hand, foot, and mouth disease (HFMD) is a familiar and distressing milestone for many parents of young children. Medically categorized as enteroviral vesicular stomatitis, it typically begins with a sudden fever, followed by a painful sore throat, painful mouth ulcers, and a distinct rash on the palms and soles. These symptoms frequently lead to a complete refusal to eat or drink, causing highly stressful days for families.

While most children recover fully within a week with supportive care, certain enterovirus strains can take a more aggressive course. In severe cases, these infections can lead to neurological or cardiovascular complications requiring urgent hospitalization. To address this risk, Sinovac is launching a large-scale Phase 3 trial of an inactivated tetravalent enterovirus vaccine, registered under the identifier NCT07611513.

What exactly are researchers looking for?

This is a rigorous Phase IIIa clinical trial designed to enroll 6,000 children between the ages of 6 and 71 months—the exact demographic most susceptible to community outbreaks in daycare centers and schools.

Participants will be randomly assigned to two groups to receive either the experimental vaccine or a placebo across a two-dose schedule spaced one month apart. The primary goal is to assess how effectively the vaccine prevents HFMD and herpangina caused by four critical enterovirus types: EV71, CA16, CA10, and CA6. Doctors will also carefully evaluate the strength of the immune response and the overall safety profile.

Why this matters to parents

The primary challenge in managing HFMD is the sheer variety of causative agents. According to the Centers for Disease Control and Prevention (CDC), while Coxsackievirus A16 is a frequent culprit, other strains change the dynamic of the disease. For instance, Coxsackievirus A6 is often tied to more widespread, severe skin symptoms, whereas the EV-A71 strain—notorious for fueling large outbreaks in East and Southeast Asia—carries a rare but serious risk of targeting the central nervous system.

Currently available commercial vaccines are monovalent, meaning they only target the EV71 strain. Sinovac's new tetravalent candidate represents a broader approach, aiming to shield children from multiple common causes of enteroviral illness with a single vaccine regimen.

Current status and the road ahead

Combining four separate viral antigens into one stable pediatric vaccine is a highly sophisticated bioengineering task. Earlier clinical data from Sinovac's bivalent development programs provided the scientific foundation necessary to advance this expanded multi-strain version into late-stage testing.

However, the launch of a Phase 3 trial is not an indicator that a commercial rollout is imminent. It marks the beginning of a thorough data-collection process to determine if the theoretical protection translates into real-world efficacy across pediatric populations.

What cannot be claimed yet

At this stage, it cannot be asserted that the tetravalent vaccine definitely prevents HFMD, reduces hospital admission rates, or guarantees total immunity for all children. The trial is in its early stages, and its performance must be rigorously tested against a placebo group before any clinical conclusions can be drawn.

The accurate takeaway is that science is working toward a more comprehensive preventive tool against common childhood enteroviruses. For parents, this is a significant and hopeful development, but routine medical recommendations must wait until the final Phase 3 data is fully analyzed and published.

Primary source: ICH GCP: NCT07611513.
Additional context: CDC: Causes of Hand, Foot, and Mouth Disease; PLOS One: EV-A71 Vaccine Efficacy Review; Sinovac Bivalent Program Background.

GLP-1 receptor agonists (such as semaglutide and tirzepatide) have revolutionized obesity treatment, becoming one of the most widely discussed medical topics globally. However, alongside their popularity, a crucial scientific question has emerged: is it possible to use diet, fiber, and microbiome management to improve the body's response to therapy and mitigate side effects?

This exact question is the focus of a new large-scale clinical trial. Registered in the international database under the identifier NCT07611552, the study will investigate the effects of inulin in overweight or obese individuals who are already taking GLP-1 receptor agonists for weight management.

What is inulin?

Inulin is a type of soluble dietary fiber that falls under the category of prebiotics. It is largely undigested in the upper gastrointestinal tract and travels to the colon, where it ferments and serves as food for beneficial gut bacteria. Because of this mechanism, inulin is frequently discussed in the context of improving the microbiome, producing short-chain fatty acids, and normalizing sugar and lipid metabolism.

However, the label "prebiotic" should not be interpreted as a guaranteed medical cure. While inulin can alter the composition of gut flora, its actual impact on weight, cholesterol levels, and tolerance to GLP-1 therapy in specific patients must be rigorously tested in clinical settings.

What exactly will the trial test?

The trial is being conducted by the Huazhong University of Science and Technology in China. It is a strict randomized, double-blind, placebo-controlled study that plans to enroll 600 adult participants.

According to the protocol, participants must be overweight or obese, have at least one weight-related complication, and have been taking a GLP-1 drug (such as semaglutide, liraglutide, or tirzepatide) for weight loss for at least three months prior to joining.

Participants will be randomly divided into two groups: one will receive 10 grams of inulin daily, while the other will receive a placebo (maltodextrin). The intervention will last for four months.

Why does this matter for people on GLP-1?

GLP-1 medications do much more than just reduce weight. They systematically affect appetite, eating behavior, blood sugar levels, lipid profiles, and overall gastrointestinal function. Against this backdrop, the interaction between medication and dietary fiber becomes a highly practical issue: how does the body react when a high-quality prebiotic is introduced to an ongoing, powerful drug regimen?

The primary endpoint for the researchers is observing changes in blood lipid levels, including total cholesterol and triglycerides. Doctors will also closely monitor secondary outcomes, such as gastrointestinal symptoms, glucose levels (HbA1c), weight changes, body fat percentage, microbiome indicators, and liver function.

Why caution is needed with this topic

A scientific foundation for inulin already exists. Systematic reviews confirm its ability to influence the microbiome and various cardiometabolic markers. However, this data is quite mixed. The actual effect depends heavily on the dosage, the individual's baseline diet, and the existing state of their gut flora.

The value of this new study lies in its narrow focus. It is not testing a broad marketing claim like "inulin for weight loss," but rather evaluating a highly specific, modern clinical scenario: the use of the supplement in patients actively undergoing GLP-1 therapy.

What we don't know yet

At this stage, it is not claimed that inulin boosts the effects of GLP-1, accelerates weight loss, alleviates nausea, or guarantees better lab results. The study is currently in the pre-recruitment phase, and no data has been generated yet.

Furthermore, inulin is not a universally benign supplement. For many people, a sudden increase in prebiotics can trigger severe bloating, gas, diarrhea, or constipation. This is precisely why gastrointestinal tolerance is listed as a specific monitoring point in the trial.

The accurate takeaway is this: medical science is looking for ways to make obesity treatment more comprehensive. Testing inulin as an adjunct to GLP-1 therapy is a promising hypothesis, but until the final results are in, patients should avoid self-prescribing high doses of prebiotics while on these medications.

Primary source: ICH GCP: NCT07611552.
Additional context: Nutrients: systematic review on inulin-type fructans; Frontiers in Nutrition; mBio: GLP-1 and gut microbiota review.

Photo by Patty Brito

High blood pressure, elevated cholesterol, blood sugar spikes, and declining kidney function all share one insidious trait: they often develop in absolute silence. A person can feel perfectly fine, maintain an active lifestyle, and be completely unaware that they are living with severe risk factors for a heart attack, stroke, or heart failure for years.

A new study launched in Sweden, U-SCREEN, is attempting to make the diagnosis of these hidden threats much more accessible. Scientists want to see if the crucial first step of risk detection can be moved out of the clinic and directly into the patient's home. The project is led by Uppsala University and is registered in the international database under the identifier NCT07614659.

How the home screening works

U-SCREEN is a randomized trial evaluating a multimodal screening approach. It is inviting residents of the Uppsala region who turn exactly 50, 55, 60, 65, 70, or 75 years old during the enrollment period to participate.

Participants will be randomly divided into two groups. The first group will continue to receive standard medical care as usual. The second group will receive a specialized home screening kit. This kit includes an automated blood pressure monitor, a self-collection kit for a dried blood spot from a finger prick, and access to a secure digital questionnaire regarding their symptoms, lifestyle, and family medical history.

The dried blood spot will allow the laboratory to assess ApoB (a marker linked to "bad" cholesterol), HbA1c (glycated hemoglobin, indicating diabetes risk), and creatinine (a measure of kidney function).

Why this matters for patients

Many cardiovascular risks are highly manageable if detected in time. Blood pressure can be lowered through lifestyle changes or medication. Elevated blood sugar can be corrected with diet. Lipid imbalances and early kidney issues also respond well to timely medical intervention.

The fundamental flaw in modern preventive medicine is that asymptomatic people rarely visit a doctor just for a checkup. U-SCREEN aims to solve this exact problem: if screening can be done comfortably at home without needing to schedule a clinic appointment, significantly more people could become aware of their risks.

What will be considered a success?

The researchers' primary goal is to determine whether this home kit uncovers more real, clinically significant risk factors than the traditional healthcare system. Furthermore, they will track whether this screening leads to actionable results: do people start preventive treatments, does it ultimately reduce the rate of cardiovascular events, and how does it impact overall quality of life and healthcare costs?

This project differs significantly from commercial "test yourself" health kits. U-SCREEN is designed to scientifically prove whether this tool works as an integrated, effective component of a public healthcare system.

What we don't know yet

At this stage, it cannot be claimed that home screening guarantees protection against heart attacks or strokes. The study has just launched, and it must prove that detecting risks at home actually leads to appropriate medical actions and improves long-term health outcomes.

Moreover, the home kit is in no way a replacement for a doctor. According to the study protocol, if any test results or blood pressure readings fall outside the normal range, the participant is given clear instructions and referred to a healthcare professional for a standard clinical evaluation and treatment plan.

The real news here is the attempt to make preventive medicine as early, convenient, and scalable as possible. If the Swedish approach succeeds, it could set a new global standard for detecting hidden health risks before they strike.

Primary source: ICH GCP: NCT07614659.
Additional context: Uppsala University: U-SCREEN; American Heart Association: Heart-Health Screenings; CDC: Heart Disease Risk Factors.

Lynch syndrome is a hereditary condition that significantly increases a person's risk of developing certain types of cancer, primarily colorectal and endometrial cancers. The root cause lies in inherited mutations in genes that normally act as "spellcheckers" to find and fix errors in DNA when cells divide.

Now, a new study preparing to launch in the Netherlands is approaching prevention from an entirely different angle. Researchers want to find out if the immune system can be trained in advance to recognize the earliest danger signals in people with this syndrome. The project, named PROTECT-Lynch and sponsored by the Radboud University Medical Center, is registered under the identifier NCT07609901.

What exactly will doctors be testing?

PROTECT-Lynch is a rigorous, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial. The study plans to enroll 372 individuals who have confirmed hereditary mutations associated with Lynch syndrome but currently show no clinical signs of cancer.

Participants will randomly receive either a placebo or an experimental dendritic cell vaccine. Dendritic cells are the "scouts" of our immune system. They capture suspicious particles and present them to killer immune cells, effectively ordering a targeted attack. In this vaccine, scientists are using dendritic cells to pre-expose the immune system to neoantigens—unusual protein fragments that inevitably appear in cells when the DNA repair mechanism is broken.

The primary endpoint for the researchers is disease-free survival. Simply put, doctors will monitor whether the vaccine can delay or completely prevent the appearance of precancerous polyps (adenomas) and malignant tumors compared to the placebo group.

Why this concept is so important

Today, people living with Lynch syndrome are locked into a lifetime of constant medical surveillance. They undergo regular colonoscopies, genetic counseling, and frequent screenings. In some cases, doctors even recommend preventive surgeries. While these measures help catch the disease early, they do not eliminate the underlying genetic risk.

The idea of preventive immunization is groundbreaking: instead of waiting for a tumor to grow, doctors are trying to intervene at a cellular level before it forms. However, because this concept is so bold, researchers urge extreme caution. The clinical trial still needs to prove that this approach actually works better than a placebo and is safe for long-term use.

Why it's not a "cancer vaccine" in the everyday sense

The word "vaccine" can be misleading here. This is not a traditional shot to prevent a viral infection, nor is it a magic bullet that grants immunity against all cancers. It is a highly complex, targeted immune therapy designed for a specific group of people with a distinct genetic profile.

Furthermore, participating in this trial does not replace standard medical care. According to the protocol, all participants must undergo a routine surveillance colonoscopy before joining to ensure they have no hidden tumors. Even if the vaccine proves highly successful in the future, it will act as a supplement to regular screening, not a replacement.

What we don't know yet

At this stage, it is preliminary to claim whether this dendritic cell vaccine prevents cancer in people with Lynch syndrome, saves lives, or will eliminate the need for colonoscopies. The trial hasn't even begun yet; patient recruitment is slated to start in late 2026.

The core news here is the launch of a definitive Phase 3 trial to test this bold hypothesis. Only time and rigorous scientific data will reveal whether preventive immune stimulation can truly protect mutation carriers from developing tumors.

Primary source: ICH GCP: NCT07609901.
Additional context: CDC: About Lynch Syndrome; NCI Dictionary.

          Photo by CDC on Unsplash

Type 1 diabetes in children is often perceived as a disease that strikes out of nowhere. A child suddenly starts drinking excessive amounts of water, needing frequent bathroom trips, losing weight, and growing weak. In some cases, the diagnosis is only made when the child is rushed to the hospital in critical condition. However, the immune system malfunction that destroys the insulin-producing cells in the pancreas actually begins months or even years before these visible symptoms appear.

Doctors are now trying to catch this "silent" phase earlier. Northwestern University is launching a new study, registered under the identifier NCT07612475, to figure out if widespread Type 1 diabetes screening can be smoothly integrated into routine pediatric well-child visits.

What exactly are they testing?

It is important to understand that this is not a clinical trial for a new drug, nor is it an attempt to cure the disease before it starts. Researchers want to evaluate how this type of screening will actually work in real-world clinics and hospitals.

Doctors will offer families a blood test to check for specific autoantibodies. These are marker proteins indicating that the immune system has begun attacking the pancreas. The study plans to include around 3,500 children. The screening will be discussed and offered during standard preventive checkups when children are 2–4, 6–8, and 11–15 years old.

Why this matters so much for parents

Type 1 diabetes does not always run in the family. The study's authors emphasize that while close relatives of diabetics have a higher risk, the vast majority of children diagnosed with Type 1 diabetes have no family history of the condition at all.

The primary danger of a late diagnosis is diabetic ketoacidosis (DKA). This is a life-threatening complication where the body desperately lacks insulin, blood sugar spikes, and the blood literally becomes dangerously acidic. Detecting the risk early via a blood test gives families and doctors something invaluable: time. Time to establish monitoring, educate parents on early warning signs, and put a clear medical action plan in place.

Why isn't everyone doing this already?

Testing all children seems like an obvious solution, but implementing it into everyday healthcare is incredibly complex. The medical system needs clear pathways: who orders the test, who explains the results to anxious parents, which specialist takes over if the test is positive, and how these additional steps are funded.

This is why the new study focuses heavily on logistics. Researchers want to see if pediatricians are willing to order the tests, if parents accept them, whether the process causes unnecessary panic, and if it overloads an already busy doctor's schedule.

What we don't know yet

At this point, it cannot be claimed that all children must take this test, or that screening prevents diabetes. A positive autoantibody result does not mean a child already has clinical diabetes; it simply indicates a high probability that the disease may develop in the future.

The real news here is the attempt to move early detection out of specialized research labs and into the offices of local pediatricians. If this approach proves practical and acceptable for families, it could fundamentally change how the medical community approaches childhood Type 1 diabetes.

Primary source: ICH GCP: NCT07612475.
Additional context: Pediatrics Open Science; Diabetes Care; The Lancet Diabetes & Endocrinology.

Pancreatic cancer remains one of the most challenging and aggressive diseases in oncology. It frequently develops silently, showing no early symptoms, and is often diagnosed at an advanced stage when it has already spread and treatment options are far more limited. Consequently, any news regarding potential methods for early detection quickly sparks widespread public interest.

However, in this field, it is crucial to separate early-stage research from established medical practice. A large-scale clinical study evaluating the Enzeavour blood test has begun in Japan, but researchers emphasize that this is not yet a proven mass-screening method or an immediate solution to the problem.

The trial registration is available in the international clinical database under the identifier NCT07605819, sponsored by Cosomil, Inc. The project is extensive, aiming to enroll approximately 10,000 asymptomatic adults who are already attending routine medical checkups or standard cancer screening programs.

Understanding the new method

The Enzeavour Pancreatic Cancer Assay is a specialized blood test. According to the study protocol, the technology measures the activity of specific enzymes at a single-molecule level, combining several biomarkers into a single risk index called the Enzeavour Score.

If this score exceeds a pre-determined threshold of 0.369, the test result is considered positive. Under the study guidelines, a positive result prompts a referral for further diagnostic imaging tailored to clinical standards, such as an MRCP, an endoscopic ultrasound, or a contrast-enhanced CT scan.

This is a vital distinction regarding how the technology works: the blood test itself does not diagnose cancer. Its sole purpose is to serve as an indicator, helping doctors identify which asymptomatic individuals might benefit from advanced, targeted imaging.

What exactly are researchers investigating?

The current project in Japan is a feasibility study rather than a trial designed to prove a direct reduction in mortality rates. At this stage, the goal is more modest: to evaluate how reliably and practically the technology performs within real-world health checkup systems and to gather the robust baseline data required for more rigorous future trials.

Physicians will monitor all participants for 12 months following their blood draw to determine how many individuals actually receive a confirmed diagnosis. This will allow researchers to calculate the test's true positive predictive value, revealing what percentage of positive scores turn out to be false alarms versus genuine warning signs.

Why this area of research is so complex

Unlike colon or breast cancer, there are currently no approved mass-screening programs for pancreatic cancer among average-risk populations. Major medical organizations, including the American Cancer Society (ACS), do not recommend routine screening for the general public. Because the disease is relatively rare, utilizing a test that lacks extreme precision would trigger an overwhelming wave of false positives, leading to widespread anxiety, unnecessary invasive procedures, and potential medical harm.

As a result, any new diagnostic tool faces exceptionally high standards. It is not enough for a test to show that it can detect abnormalities; researchers must prove that its widespread use does more clinical good than harm.

What cannot be claimed yet

At this point, it absolutely cannot be stated that the Enzeavour test reliably catches early-stage pancreatic cancer or is ready for use in everyday clinics. The study is currently in the recruitment phase, and final data has not yet been generated.

Furthermore, a positive test result must never be interpreted as a definitive verdict. It is merely a clinical prompt for standard diagnostic imaging. In modern medicine, there is still no "magic bullet" or single-drop blood test that can replace a physician's comprehensive evaluation, advanced scans, and biopsy confirmation. Science is moving forward, but this method still has a long road ahead before it reaches everyday clinical guidelines.

Primary source: ICH GCP: NCT07605819.
Additional context: UMIN Clinical Trials Registry: Enzeavour feasibility study; American Cancer Society: pancreatic cancer early detection; USPSTF: pancreatic cancer screening recommendation.

Bowel screening is a topic that causes a lot of anxiety. Today, one of the most common and simple baseline checks is the Fecal Immunochemical Test (FIT), which looks for hidden blood in the stool. It is an excellent, accessible tool that helps doctors spot early warning signs. But patients often harbor a logical fear: what if the test comes back negative, but a dangerous hidden polyp or early cancer is still there?

No basic screening test offers a 100% guarantee. That is exactly why medical science is constantly looking for additional safety nets. A new clinical trial, registered in the international database under the number NCT06612281, aims to test the accuracy of a system called Gixam in people whose baseline FIT results were negative.

What exactly will be tested?

This study will involve individuals whose stool tests did not reveal anything suspicious, but who are still scheduled to undergo a colonoscopy. Doctors want to compare two things: the risk prediction generated by the , and the actual physical reality the doctor sees during the endoscopic examination of the bowel.

The researchers' main goal is to understand how accurately this additional tool can predict a problem where the standard stool test remained silent.

Why this matters so much

Bowel cancer is a highly preventable disease if dangerous polyps are found and removed before they turn into tumors. However, sending every single patient for a colonoscopy isn't feasible: it is a complex procedure that requires significant preparation, time, and medical resources.

If doctors gain a reliable supplementary tool to assess risk, they will have a clearer picture of who urgently needs a full physical examination. This is especially crucial for people whose basic tests looked fine but who might still carry hidden risks.

What we don't know yet

At this stage, it absolutely cannot be claimed that the Gixam system finds cancer that a regular test "missed," or that it can replace a full colonoscopy. This is currently just an accuracy check for a new technology.

The real news here isn't the arrival of a "magic test," but rather that medicine is trying to illuminate a very important gray area in diagnostics. Doctors are searching for ways to ensure that a negative test result gives patients even more confidence and peace of mind about their health.

Primary source: ICH GCP: NCT06612281.

Atrial fibrillation is a common condition where the heart beats irregularly. The real danger isn't the fluttering sensation itself, but what happens inside the heart. Because blood doesn't flow smoothly, it can pool and form clumps, or clots. If one of these clots breaks loose and travels to the brain, it causes a stroke. To prevent this, doctors usually prescribe blood thinners.

However, there is a major problem: regular blood thinners are not safe for everyone. For some people, these medications make them bleed too easily and too much, forcing doctors to stop the treatment entirely. It is specifically for this vulnerable group of people that the company Regeneron is launching a massive new study.

The project is called ROXI-INCLINE, and it is officially registered in the international clinical trials database under the number NCT07430956.

What exactly are researchers testing?

The study will involve over 2,600 adults with an irregular heartbeat who cannot take standard blood-thinning pills for medical reasons. Doctors will test two new experimental medications: REGN7508 and REGN9933.

Participants will be randomly placed into groups: some will receive the new drugs, while others will receive a dummy pill (placebo). The main goal is to find out if these new medications can reliably protect people from strokes and dangerous blood clots without causing harm.

How the new medications work

Both new drugs are designed to work much more carefully than traditional blood thinners. They target just one specific protein in the body that helps blood clot, known as Factor XI.

Standard blood thinners act a bit like a sledgehammer. They block the body's ability to form both the bad clots that cause strokes and the good clots you need to stop bleeding if you accidentally cut yourself. The new drugs aim to be much more precise. Scientists hope that by blocking just this one protein, they can stop dangerous clots from forming inside the blood vessels, while still allowing the body to naturally heal everyday cuts and scrapes.

Why this matters so much

Patients who cannot take standard blood thinners are currently in a very scary situation—they have to live with a constant, unprotected risk of having a stroke. If these new medications can prevent blood clots without the risk of severe bleeding, it would be a life-changing breakthrough for thousands of people.

The ROXI-INCLINE study is so important because it isn't just about a scientific theory; it is trying to solve a huge, everyday problem for real people who currently have no safe treatment options.

What we don't know yet

At this point, it is too early to say that these new drugs are completely safe, will never cause bleeding, or are guaranteed to prevent a stroke. They are still experimental, and scientists need to finish this large study to gather solid proof of how well they actually work in real life.

The news right now is that this large-scale testing has officially begun. Only the final results will show whether this new approach can truly protect patients without causing dangerous side effects.

Primary source: ICH GCP: NCT07430956.

GSK is launching a clinical trial for experimental vaccines against RSV and hMPV in young and older adults. This is not a ready-made defense against "all winter viruses," but an early-stage test of safety and immune response.

Following the pandemic, people have become much more aware of respiratory viruses. However, the spotlight usually falls on the flu, COVID-19, and RSV (respiratory syncytial virus). Yet, there is another virus that the general public knows far less about: hMPV, or human metapneumovirus. It can similarly cause a cough, fever, nasal congestion, shortness of breath, bronchitis, and pneumonia, particularly in young children, older adults, and immunocompromised patients.

Now, pharmaceutical giant GSK is launching a new trial to study experimental vaccines against both RSV and hMPV. The trial is registered on the international ICH GCP portal under the identifier NCT07628049.

What exactly will be tested?

According to the registry data, this is a Phase 1/2 clinical trial. Its primary objective is to evaluate the safety, reactogenicity, and immune response to various formulations of an experimental combined RSV/hMPV vaccine, as well as a standalone experimental hMPV vaccine.

Reactogenicity refers to the expected physical reactions after vaccination, such as pain at the injection site, fever, fatigue, or muscle aches. Immune response measures how actively the body produces protective antibodies and mounts a specific defense against the viruses.

The study plans to enroll 1,808 adult participants. The protocol notes that both younger and older adults will be included. The trial is scheduled to start in June 2026, and its current status is listed as not yet recruiting.

Why does this matter?

RSV is already well-recognized by doctors and patients as a virus that poses a severe threat to infants, the elderly, and individuals with chronic medical conditions. In recent years, approved RSV vaccines for adults have entered the market. The CDC currently recommends RSV vaccination for everyone aged 75 and older, as well as adults aged 50–74 who are at an increased risk of severe disease.

Human metapneumovirus (hMPV) is less familiar to the public, despite belonging to the same virus family as RSV. According to the CDC, hMPV can infect people of any age, with symptoms often mirroring a common cold. However, in vulnerable groups, the infection can move deeper into the bronchi and lungs, leading to severe complications.

Why a combined RSV and hMPV vaccine makes sense

These viruses cause similar respiratory symptoms and target the exact same vulnerable populations—older adults and patients with chronic illnesses. Therefore, the concept of a combined vaccine is highly logical: if the immune system can be primed against two related respiratory threats with a single shot, seasonal prevention would become much simpler.

But for now, this remains a scientific hypothesis. An early-stage Phase 1/2 trial is not designed to prove whether the vaccine actually prevents real-world illness during cold season. At this stage, researchers are primarily looking to see if the proposed formulas are safe and whether they trigger a sufficiently strong immune response in the lab.

What cannot be claimed yet

At this point, it is absolutely incorrect to claim that the new combined RSV/hMPV vaccine already protects against infections, reduces hospitalizations, or will be available in clinics soon. It should also not be marketed as a universal "cold vaccine": there are hundreds of respiratory viruses, and the RSV/hMPV duo is only a part of that picture.

The real value of this news lies elsewhere: a major pharmaceutical company is taking the next step in the evolution of seasonal infection prevention. Following the successful rollout of RSV vaccines, scientific focus is naturally shifting to hMPV—a virus that has long flown under the radar but causes very real harm.

Primary source: ICH GCP: NCT07628049.
Additional context: CDC: About Human Metapneumovirus; WHO: Respiratory syncytial virus; CDC: RSV vaccine guidance for adults.

A clinical trial for the experimental drug bofanglutide is being prepared in Latin America for adults with overweight or obesity. The medication will be directly compared to semaglutide, but medical experts emphasize this is not yet proof that it is superior or more convenient for patients.

GLP-1 medications have become one of the most widely discussed topics in modern medicine. Used to treat type 2 diabetes and obesity, every new molecule in this class quickly generates intense interest. However, for a patient, the question is not just how much weight the drug helps shed. Tolerability, safety, accessibility, and the convenience of maintaining the treatment regimen over months are equally crucial.

This is precisely why a new clinical trial, registered in the ICH GCP database under the identifier NCT07622810 (also known as BALANCE-OBS), is drawing the scientific community's attention. The study will compare bofanglutide (GZR18) with semaglutide in Latin American adults living with overweight or obesity.

What is this drug?

Bofanglutide is an experimental GLP-1 receptor agonist. It belongs to the same broad therapeutic class as semaglutide but features a fundamentally different dosing schedule. In this trial, bofanglutide will be administered subcutaneously once every two weeks, whereas the semaglutide in the comparison group will be given on its standard once-weekly schedule.

It is this "once every two weeks" regimen that makes the topic highly relatable to a broad audience. Theoretically, fewer injections could be significantly more convenient for people. However, this remains to be proven in practice: patient comfort must never come at the expense of clinical efficacy and safety.

What exactly will be tested?

According to the registry data, BALANCE-OBS is a Phase 3 trial sponsored by Carnot Laboratories. It plans to enroll 352 adult participants with overweight or obesity. Currently, the trial's status is listed as "not yet recruiting," with the official start scheduled for September 2026.

The primary question researchers want to answer is whether bofanglutide reduces body weight after 36 weeks of treatment as effectively as (or better than) semaglutide. In parallel, researchers will carefully evaluate metabolic markers, cardiovascular risk factors, changes in quality of life, as well as overall safety and tolerability.

Why does this matter?

Obesity is not a cosmetic issue; it is a complex, chronic disease. It is intrinsically linked to an increased risk of type 2 diabetes, hypertension, heart disease, fatty liver disease, and numerous other complications. According to the World Health Organization (WHO), hundreds of millions of adults worldwide live with obesity, and even more are overweight.

Against this backdrop, a direct comparison of a new GLP-1 medication with the recognized standard (semaglutide) is a critical step. This is not because one drug can already be declared the winner, but because medicine is gradually moving past the question of "do GLP-1s work in principle?" to a much more practical one: which specific option, for which patients, and with what balance of benefits and risks works best?

What science already knows

Bofanglutide has previously undergone a Phase 2b trial involving adults in China with overweight or obesity. The published research noted that the drug reduced body weight significantly more than a placebo. The most frequent adverse events were predictably gastrointestinal reactions, which is a typical profile for all GLP-1 agonists.

But these early data cannot automatically be generalized to all patients. The BALANCE-OBS trial will take place in a completely different population, and most importantly, it will feature an active comparison against a strong competitor rather than just a placebo. This is exactly why the new Phase 3 trial is needed to show how convincing bofanglutide looks in a real-world clinical setting.

What cannot be claimed yet

At this point, it is absolutely incorrect to state that bofanglutide is better than semaglutide, safer, more convenient, or guaranteed to be the new replacement for existing drugs. The trial in Latin America has not even begun and has yielded no results.

A more accurate and cautious takeaway is this: a large-scale Phase 3 trial is in preparation, where a promising new biweekly GLP-1 will undergo the ultimate test—a direct comparison with the current market leader. This is an excellent news hook showing scientific progress, but it is not yet a ready clinical answer for patients.

Primary source: ICH GCP: NCT07622810.
Additional context: Signal Transduction and Targeted Therapy: phase 2b bofanglutide trial; Gan & Lee: bofanglutide phase 2b results; WHO: obesity and overweight.

Most people associate GLP-1 medications solely with treating type 2 diabetes and promoting weight loss. However, in recent years, the medical community has been discussing this class of drugs in a much broader context: as a potential way to influence not just blood sugar and body mass, but also severe cardiovascular and renal risks.

Now, a major new step is being taken in this direction. A clinical trial registry entry, NCT07625774, has been published on the ICH GCP portal. The study will test the experimental drug HRS-7535 in patients with chronic kidney disease (CKD), sponsored by Shandong Suncadia Medicine Co., Ltd.

What is this drug?

HRS-7535 is an experimental oral small-molecule GLP-1 receptor agonist. Simply put, it operates on the same basic biological logic as the famous blockbuster weight-loss injections, but it comes in a convenient pill form and has its own distinct clinical development program.

Early data on HRS-7535 has already been published regarding patients with type 2 diabetes. In Phase 2 trials, the drug successfully lowered HbA1c levels compared to a placebo, with a side-effect profile generally consistent with what is expected from GLP-1 agonists—primarily gastrointestinal reactions. However, these findings cannot be automatically assumed to apply to patients with chronic kidney disease.

What exactly will the new trial test?

This new study is a full-scale Phase 3 trial. According to the ICH GCP data, it plans to enroll a staggering 3,690 participants diagnosed with chronic kidney disease. Patients will be randomly assigned to receive either HRS-7535 or a placebo. The primary objective is to comprehensively evaluate the drug's efficacy and safety profile specifically within this vulnerable patient population.

This is a crucial detail: we are not talking about a small, preliminary check, but a massive clinical trial. Still, reaching Phase 3 does not mean the drug has already proven its worth. It simply means the scientific hypothesis is now being tested on a much larger scale, focusing on highly clinically significant outcomes.

Why does this matter?

Chronic kidney disease is insidious because it often develops silently. According to the Centers for Disease Control and Prevention (CDC), CKD affects approximately 14% of adults in the United States—meaning more than one in ten people have it. The disease can sharply increase the risk of cardiovascular complications, progress to kidney failure, and drastically reduce a person's quality of life.

Interest in the potential of GLP-1s in nephrology surged following highly successful trials involving semaglutide. In early 2025, the FDA officially expanded the indications for Ozempic, approving it to reduce the risk of kidney disease progression, kidney failure, and cardiovascular death in adults with type 2 diabetes and CKD.

But it is vital to remember: HRS-7535 is not semaglutide, and it is not an approved treatment. This new study is designed to answer whether this specific molecule holds its own proven benefits and an acceptable safety profile for kidney health.

What cannot be claimed yet

At this stage, it absolutely cannot be stated that HRS-7535 protects the kidneys, prevents the need for dialysis, or can replace existing CKD treatments. The registration of a massive Phase 3 trial is an excellent news hook, but it is not a medical result.

A more accurate and cautious takeaway is this: the application of GLP-1 therapies continues to expand rapidly, and a new oral pill is now undergoing rigorous testing for chronic kidney disease. If the results are compelling, patients may gain a convenient new treatment option. But until the final data is published, science must wait.

Primary source: ICH GCP: NCT07625774.
Additional context: CDC: Chronic Kidney Disease in the United States; Diabetes: phase 2 data on HRS-7535 in type 2 diabetes; FDA approval context for semaglutide in type 2 diabetes and CKD.

A new study launching in Hong Kong and Vietnam will analyze ctDNA mutations and methylation in the blood of patients with suspicious lung nodules. The goal is not to replace CT scans or biopsies, but to determine whether this blood test can more accurately assess the risk of lung cancer.

A small lung nodule found on a CT scan is a discovery that often triggers intense anxiety. For a patient, it can sound almost like a death sentence, even though in practice, many such nodules turn out to be benign. The problem is that a single scan cannot always confidently distinguish between early-stage cancer and a harmless scar from inflammation, an infection, or another non-threatening cause.

It is exactly this diagnostic gray area that researchers from Hong Kong and Vietnam are trying to better understand. A new clinical trial, registered in the ICH GCP database under the identifier NCT07615556, focuses on ctDNA mutations and methylation as potential biomarkers for early lung cancer in people with suspicious nodules.

What exactly will be tested?

The study plans to enroll 200 participants: 100 in Hong Kong and 100 in Vietnam. All participants must have suspicious lung nodules detected on a chest CT scan. According to the protocol description, this involves non-calcified nodules ranging from 0.5 to 30 mm in size, or nodules showing increased uptake on a PET scan, if one has already been performed.

Blood samples will be collected upon enrollment and again six months later. Researchers will analyze the blood for ctDNA (circulating tumor DNA)—fragments of DNA that tumor cells can shed into the bloodstream—as well as specific DNA methylation patterns. In parallel, participants will undergo a follow-up low-dose chest CT scan at the six-month mark.

The primary objective is to see how well the blood test results correlate with a definitive lung cancer diagnosis or the persistence of a suspicious nodule. The secondary goal is to evaluate the sensitivity and specificity of these biomarkers—essentially, how effectively they help distinguish malignant nodules from benign ones.

Why scans alone are sometimes not enough

Lung nodules are evaluated based on numerous characteristics: size, shape, density, edges, growth over time, smoking history, age, comorbidities, and other risk factors. Sometimes, watchful waiting and a follow-up CT scan are sufficient. In other cases, a PET-CT, bronchoscopy, or biopsy is required.

However, each option has limitations. Watchful waiting can leave a patient in a state of high anxiety for months. A biopsy provides crucial information but is an invasive procedure, especially if the nodule is small or located deep within the lung. This makes the idea of a supplementary blood test highly appealing: it could help doctors more precisely determine who truly needs an aggressive workup and who can safely continue observation.

What is DNA methylation?

Methylation refers to chemical "tags" on DNA that regulate gene activity. In tumor cells, these tags can differ significantly from those in normal cells. If fragments of tumor DNA enter the bloodstream, they can theoretically be detected and used as a reliable risk signal.

This study utilizes the SPOTMAS Lung assay, a testing approach that analyzes multiple types of features in cell-free DNA. But it is important to emphasize: this is not yet a routine screening tool or a ready-made way to independently "check for lung cancer." It is currently being studied specifically in people who already have suspicious clinical findings after a CT scan.

Why this matters for non-smokers

The project description explicitly highlights the Asian context. Researchers in Hong Kong and Vietnam are drawing attention to the unique epidemiology of lung cancer in the region, particularly the high incidence among women and non-smokers. This is a critical topic because the public perception of lung cancer is often solely tied to smoking, even though the disease frequently occurs in people with no obvious history of tobacco use.

If blood biomarkers can effectively complement CT scans and clinical data, it could help doctors more accurately assess risk across diverse patient groups. But that remains a big "if": the study must first prove how reliable this approach actually is in real-world practice.

What cannot be claimed yet

At this point, it cannot be claimed that a ctDNA and methylation blood test can detect lung cancer in anyone who wants to be tested, nor does it replace CT scans, PET-CTs, or biopsies. It also cannot be guaranteed that such a test will entirely eliminate the need for invasive procedures.

The accurate takeaway from this news is much more cautious: scientists are currently testing whether a blood test can serve as an additional tool for evaluating already-discovered suspicious lung nodules. If the data holds up, this approach could reduce false alarms and help doctors more quickly identify and treat the nodules that truly require immediate action.

Primary source: ICH GCP: NCT07615556.
Additional context: Asian Pacific Society of Respirology: project summary; American Lung Association: lung nodule follow-up guidelines; Lung Cancer: ctDNA methylation model for pulmonary nodules.

Eli Lilly is launching a clinical trial of lepodisiran for people with high Lipoprotein(a)—an inherited risk factor for heart attacks and strokes. Researchers aim to find out if the new drug can do more than just lower blood test numbers by actually impacting coronary plaques.

Most people associate cholesterol management with diet, weight, and lifestyle changes. But there is another metric that patients often only discover by accident: Lipoprotein(a), or Lp(a). It is frequently referred to as a "hidden" cardiovascular risk because Lp(a) levels are largely determined by genetics and remain virtually unaffected by exercise or a healthy diet.

Now, this inherited risk factor is the focus of a new clinical trial by Eli Lilly. The trial, registered in the ICH GCP database under the identifier NCT07613294 and known as ACCLAIM-CTA, will test the experimental drug lepodisiran in adults with elevated Lp(a) who already have atherosclerotic cardiovascular disease or are at high risk for a first major cardiovascular event.

What is Lp(a) and why is it making headlines?

Lp(a) is a particle in the blood similar to "bad" LDL cholesterol, but it carries an additional protein component. When Lp(a) levels are consistently high, the risk of developing atherosclerosis, heart attacks, and strokes increases significantly. A person can feel perfectly healthy and have no idea there is a problem unless a doctor specifically orders this blood test.

The American Heart Association (AHA) notes that Lp(a) levels are primarily inherited. According to their data, approximately one in five people has elevated Lp(a). This makes the topic highly relevant to a broad audience: a person might lead an ideal, active lifestyle but still carry this hidden genetic burden.

What exactly will the trial test?

ACCLAIM-CTA is a Phase 3, randomized, double-blind, placebo-controlled trial. According to the ICH GCP registry, it plans to enroll 252 adult participants.

Patients will receive subcutaneous injections of either lepodisiran or a placebo. The primary goal is to evaluate how the drug affects the volume and type of plaque in the coronary arteries compared to the placebo. To measure this, researchers will use CCTA (Coronary Computed Tomography Angiography), an advanced imaging technique for the heart's blood vessels.

The primary endpoint of the study is the percentage change in non-calcified plaque volume from baseline to week 104. Simply put, scientists want to see more than just a drop in Lp(a) on a lab report; they want to observe real, positive changes in the structure of atherosclerosis inside the arteries.

Why is this more important than just "lowering a number"?

For a patient, a perfect lab result is not the ultimate goal. The crucial clinical question is: if we lower Lp(a) with medication, will it actually reduce the risk of heart attacks, strokes, or plaque progression?

Early studies of lepodisiran have already demonstrated its ability to cause deep and prolonged reductions in Lp(a). For instance, data shared by the Cleveland Clinic from a Phase 2 trial showed that a single 400 mg dose lowered median Lp(a) levels by about 94% between days 60 and 180. However, lowering a blood marker does not automatically prove that a drug prevents heart attacks or clears dangerous plaques.

This is why ACCLAIM-CTA is so compelling. It looks directly at the heart's arteries using precise imaging. This represents a vital intermediate step between "the blood number went down" and "fewer people are having severe heart attacks."

What cannot be claimed yet

At this stage, it absolutely cannot be stated that lepodisiran prevents heart attacks, stops strokes, or "cleans out arteries." The ACCLAIM-CTA trial has not produced any results yet. In fact, according to the ICH GCP registry, its status is currently "not yet recruiting."

Furthermore, lepodisiran should not be viewed as an available treatment for high Lp(a). It remains an investigational drug, and its actual clinical benefit in preventing real-world cardiovascular events must be rigorously proven in large, multi-year outcome trials.

The strength of this news lies in how it addresses a very common human question: why do some people suffer from heart disease despite eating right and having normal standard cholesterol? Lp(a) is a crucial part of that answer, and science is now actively testing tools to manage this specific risk.

Primary source: ICH GCP: NCT07613294.
Additional context: American Heart Association: Lipoprotein(a); Cleveland Clinic: phase 2 lepodisiran trial; JAMA: phase 1 lepodisiran trial.

Pfizer is launching a study to evaluate the safety of taking a second dose of rimegepant during a migraine attack if the pain does not fully resolve or returns. While this addresses a highly practical question for patients, medical experts emphasize that it is not yet an approved treatment rule.

A migraine is rarely just a standard headache. An attack can be accompanied by nausea, sensitivity to light and sound, and the feeling that normal life has come to a complete halt. For patients, the question isn't just "is there a medication?", but a more practical one: what should be done if the first dose doesn't completely work?

This exact scenario is the focus of a new Pfizer clinical trial, registered in the ICH GCP database under the identifier NCT07609914. Researchers aim to assess the safety, tolerability, and efficacy of redosing rimegepant during an acute migraine attack in adults.

What is rimegepant?

Rimegepant belongs to a class of drugs known as gepants. It specifically blocks the CGRP receptor—a molecule that plays a significant role in the mechanisms of migraine pain. In the U.S., the drug is marketed under the brand name Nurtec ODT and is approved for adults both to treat acute migraine attacks and to prevent episodic migraines.

It is neither a triptan nor a traditional painkiller. Gepants emerged as a distinct class of medication targeting one of the key biological pathways of a migraine. This is particularly important for patients who cannot tolerate classic triptans or for whom they are ineffective.

What exactly will be tested?

According to the ICH GCP registry, this is a Phase 4 study. This means it is not the initial testing of a brand-new compound, but rather a deeper, supplementary investigation of an already approved drug in a specific clinical situation.

The trial plans to enroll 400 adult patients with migraines. Participants will take rimegepant 75 mg in the form of an orally disintegrating tablet (ODT) to treat attacks of moderate or severe intensity.

The key aspect of the trial is the option to redose. If a participant is not pain-free approximately two hours after the initial dose, or if the headache returns after initial relief, the protocol allows for a second 75 mg dose of rimegepant within 24 hours of the first.

Why does this matter?

For people living with migraines, an incomplete response to treatment is a frequent and very real problem. Sometimes a medication reduces the intensity of the pain but fails to restore the person to normal activity. Other times, the pain subsides only to return later the same day. In these situations, patients and doctors are forced to look for additional relief options.

This is why the study is of broad interest. It does not promise a "stronger" migraine cure, but rather tests a narrow, highly relevant question: how safe and effective is taking a second dose of rimegepant during a single attack if the first dose fell short?

Why caution is needed with this topic

Currently, according to the official FDA prescribing information for Nurtec ODT, the maximum allowed dose of rimegepant in a 24-hour period is 75 mg (one tablet). The label also notes that the safety of using more than 18 doses in a 30-day period has not been established.

Therefore, this new study must not be interpreted as permission to take a second pill on your own. On the contrary, its purpose is to rigorously test an approach that should not yet be adopted as everyday advice. Redosing is being studied exclusively within a clinical protocol, with strict inclusion criteria and medical oversight.

What cannot be claimed yet

At this stage, it cannot be claimed that taking two doses of rimegepant in 24 hours is safe for general use or works better for migraines than the currently approved regimen. The study has yet to gather reliable data on tolerability, potential side effects, and the actual clinical benefit of this approach.

The strength of this news is that it directly addresses everyday patient experiences. Many have faced a situation where an attack seemed to weaken but didn't end. Now, this scenario is being studied officially—not as an internet forum tip, but as a serious clinical question requiring evidence-based answers.

Primary source: ICH GCP: NCT07609914.
Additional context: FDA prescribing information for Nurtec ODT; The Journal of Headache and Pain: safety study of once-daily rimegepant 75 mg.

Yale University is launching a clinical trial of psilocybin-assisted therapy for patients with Parkinson’s disease and depression. Interest in the approach has surged following a recent pilot study, but experts warn this is an early stage of research and it is still too soon to call it a proven treatment.

Parkinson’s disease is traditionally associated with tremors, stiffness, and slowed movements. However, for many patients, the non-motor symptoms—such as deep depression, anxiety, sleep disturbances, apathy, and a sharp decline in overall quality of life—are just as debilitating a part of the diagnosis.

This is why the medical community's attention has been drawn to a new Yale University clinical trial, registered in the ICH GCP database under the identifier NCT07610369. Researchers aim to determine whether therapy utilizing psilocybin can safely and effectively alleviate symptoms of depression in people living with this neurodegenerative condition.

What exactly will be studied?

Psilocybin is a psychoactive substance that is currently being heavily researched under strictly controlled clinical conditions for various psychiatric disorders. It is crucial to understand that this trial is not about recreational use or finding a "natural remedy." Participants will receive the drug exclusively in a medical setting, under constant clinical supervision, and in combination with professional psychotherapeutic support.

According to the registry, this is a Phase 2 randomized controlled trial. It plans to enroll 40 participants with clinically confirmed early to moderate-stage Parkinson’s disease who also have at least moderate depression.

Patients will undergo two dosing sessions: starting with a low dose (often referred to as a "microdose") and progressing to a higher dose. Mandatory psychotherapy sessions are scheduled before and after each drug administration. Medical observation of the participants will continue for up to three months following the second session.

Why is this particularly important for Parkinson's?

Depression in Parkinson’s disease is not simply a psychological reaction to a severe diagnosis. It is often an organic part of the disease itself, directly linked to structural and chemical changes in the brain. Because of this, standard antidepressants and conventional treatment approaches do not always work as effectively as desired.

For patients, this is a highly practical issue. Even if motor symptoms are partially controlled by medication, depression can devastate daily life: it saps motivation, exacerbates physical fatigue, and hinders effective rehabilitation and communication with loved ones.

Why is this topic emerging now?

The surge of interest in this trial is largely due to the results of a previous, smaller study. In an open-label pilot trial, 12 participants with Parkinson’s disease and symptoms of depression or anxiety received psilocybin alongside psychotherapy. The authors reported no serious adverse effects and noted signs of improved mood, reduced anxiety, as well as some positive shifts in cognitive and motor metrics.

However, that pilot had significant limitations: a very small sample size (only 12 people), an open-label design (meaning participants knew what they were taking), and no placebo group. Under such conditions, science cannot confidently separate the drug's actual biological effect from the placebo effect, patient expectations, and the benefits of talking with a therapist.

The new Yale University study, conducted in partnership with the University of California, San Francisco (UCSF), is designed to be a much more rigorous test. Researchers intend not only to evaluate the dynamics of depressive symptoms using clinical scales but also to attempt to understand what specific changes are occurring in the patients' brains.

What cannot be claimed yet

At this stage, it absolutely cannot be stated that psilocybin cures depression in Parkinson’s disease, improves motor functions, or slows the progression of the disease. Furthermore, the encouraging results of a small pilot study cannot be automatically generalized to all patients with this diagnosis.

Serious safety questions also remain. Psilocybin can profoundly affect perception, emotions, blood pressure, and overall mental state. For individuals with neurodegenerative changes, this is a high-risk zone, which is exactly why such trials are conducted exclusively in tightly controlled environments with strict candidate screening.

The primary value of this news does not lie in the promise of a quick, "magical" cure. Rather, it is that depression in Parkinson’s is finally being addressed as an independent, severe clinical problem that requires fundamentally new approaches and high-quality, evidence-based research.

Primary source: ICH GCP: NCT07610369.
Additional context: Yale School of Medicine: New Clinical Trial Aims to Treat Depression in People with Parkinson’s Disease; Neuropsychopharmacology: Psilocybin therapy for mood dysfunction in Parkinson’s disease.

Novo Nordisk is launching a trial of cagrilintide for individuals with obesity who had to stop GLP-1 therapy due to gastrointestinal side effects. This is not a ready-made "Ozempic alternative," but rather an early tolerability test for a medication with a completely different mechanism of action.

GLP-1 medications have transformed the treatment of obesity and type 2 diabetes, but they are not suitable for everyone. A significant number of patients are forced to discontinue therapy due to severe gastrointestinal side effects, such as nausea, vomiting, diarrhea, constipation, or pronounced discomfort.

For this specific group, Novo Nordisk is initiating a new clinical trial for the drug cagrilintide. The trial is registered on the ICH GCP portal under the identifier NCT07607587. The full title reflects its primary objective: to evaluate the tolerability of cagrilintide in people with obesity who have previously discontinued GLP-1 receptor agonists due to gastrointestinal adverse events.

What is cagrilintide?

It is important to note that cagrilintide is not another GLP-1 drug. It is a long-acting analogue of amylin—a hormone naturally involved in regulating appetite and the feeling of fullness. In simple terms, this medication operates through a different biological pathway than semaglutide and similar drugs.

This is precisely why the topic is highly relevant. While there is currently a lot of hype surrounding GLP-1s, real-world clinical practice faces a much more grounded and pressing question: what options are available for people with obesity who simply cannot tolerate these popular medications?

What exactly will be tested?

According to the ICH GCP registry, this is a randomized, double-blind trial. Participants will be randomly assigned to receive either cagrilintide or a placebo. The medication is administered subcutaneously. The treatment period is set for 26 weeks, with the entire clinical observation lasting approximately eight months.

The study plans to enroll 114 adults with obesity. Key inclusion criteria require a body mass index (BMI) of 30 kg/m² or higher, along with a documented history of GLP-1 treatment that was stopped specifically because of stomach or intestinal issues.

Notably, this trial is not designed for people with diabetes. The exclusion criteria clearly rule out individuals with type 1 or type 2 diabetes, elevated HbA1c levels in the diabetic range, and recent use of glucose-lowering medications.

Why does this matter?

The main intrigue of this study is not whether cagrilintide will prove "stronger" than current weight-loss blockbusters. Instead, the focus is on quality of life: will people who could not tolerate GLP-1 therapy be able to remain on a standard or higher dose of cagrilintide by week 26?

This makes the news less sensational, but far more meaningful for actual patients. For an individual, the abstract percentage of weight lost is often secondary to the ability to undergo treatment without debilitating side effects that disrupt daily life.

What cannot be claimed yet

At this stage, it cannot be stated that cagrilintide is a proven alternative to GLP-1s for patients with obesity. Furthermore, there are no guarantees that it will definitely be better tolerated by those who have already quit GLP-1s due to GI distress.

Cagrilintide already has published early data regarding its efficacy in obesity, including a study in The Lancet. However, this new trial is designed to answer a distinct question: not just whether the drug can induce weight loss, but whether it serves as a viable "backup plan" when first-line therapy is intolerable.

An honest takeaway is that this research should not be viewed as a promise of a "perfect weight-loss injection," but as an important step toward personalized medicine. Not all patients respond to the same mechanisms, and medical science is gradually exploring more individualized treatment options.

Primary source: ICH GCP: NCT07607587.
Additional context: The Lancet: once-weekly cagrilintide for weight management.

A new clinical trial, FAVES-B, is preparing to launch in the U.S. to determine whether the non-hormonal drug fezolinetant—currently used for hot flashes—impacts vascular and cognitive health. While this explores a crucial question, experts emphasize that it does not yet prove the treatment protects the heart or brain.

Menopause hot flashes are often described as a sudden wave of heat, sweating, facial flushing, and nighttime awakenings. For many women, this is not merely a "minor discomfort," but a disruptive symptom that interferes with sleep, work, and daily life.

Now, researchers are looking at this issue through a broader lens. A clinical trial, NCT07606664 (also known as FAVES-B), has been registered in the U.S. Its goal is to determine whether fezolinetant impacts vascular and cognitive health in women experiencing moderate to severe menopausal hot flashes and night sweats.

What is this drug?

Fezolinetant is a non-hormonal medication. In the U.S., it is marketed under the brand name Veozah and is FDA-approved for the treatment of moderate to severe vasomotor symptoms due to menopause—namely, hot flashes and night sweats.

It does not function like traditional hormone therapy. Instead, the drug blocks the neurokinin 3 (NK3) receptor, which plays a role in the brain's thermoregulation mechanisms. Simply put, it intervenes in the system that can easily trigger a "heat signal" during menopause.

What exactly will the new study test?

FAVES-B is a Phase 3, randomized, double-blind, placebo-controlled trial. According to the registry, it plans to enroll 220 women with moderate to severe hot flashes and night sweats.

Participants will be randomly assigned to one of two groups: one will take 45 mg of fezolinetant once daily for 12 weeks, while the other will receive a placebo. Neither the participants nor the research team will know who is receiving the active drug and who is getting the placebo tablet.

The primary interest of the study goes beyond just the frequency of hot flashes. Researchers will evaluate vascular function and verbal memory—the ability to remember and recall words. They will also track sleep patterns and objective measures of hot flashes.

Why does this matter?

For a long time, hot flashes were viewed primarily as an unpleasant but temporary symptom of menopause. However, in recent years, there has been growing interest in whether severe and frequent vasomotor symptoms might be linked to broader health risks, such as declining vascular health, poor sleep quality, and cognitive changes.

This is why the trial is of interest to a wide audience. It does not promise that the drug will "protect the brain" or "prevent heart disease." But it asks a crucial question: if hot flashes are effectively reduced, will the metrics associated with vascular and brain health also improve?

What cannot be claimed yet

According to the trial registry, FAVES-B is not yet recruiting participants; the estimated start date is September 2026. This means there are no results yet.

It cannot be claimed that fezolinetant improves memory, protects blood vessels, or reduces the risk of dementia and cardiovascular diseases. So far, the drug has proven its efficacy specifically for moderate to severe menopausal hot flashes, and this new research is designed to explore these secondary questions.

There is also an important safety consideration. The current FDA prescribing information for Veozah includes a warning about the risk of liver damage and the need to monitor liver blood tests before starting and during treatment. Therefore, any discussions about the drug's expanded benefits must be accompanied by a careful review of its risks.

The core news here is not the arrival of a "memory drug for menopause." Rather, it is that a well-known non-hormonal treatment for hot flashes is now being studied in a much broader context—encompassing vascular health, brain function, sleep, and overall quality of life.

Primary source: ICHGCP: NCT07606664.
Additional context: FDA: approval of Veozah / fezolinetant; FDA prescribing information for Veozah.

A small trial of the drug HEC88473 in women with polycystic ovary syndrome (PCOS) has been registered in China. Researchers aim to discover if a dual GLP-1/FGF21 mechanism can address the metabolic imbalances of PCOS, though this remains an early-stage investigation, not a proven treatment.

Polycystic ovary syndrome (PCOS) is frequently viewed simply as a gynecological issue—marked by irregular cycles, acne, excess hair growth, or fertility challenges. But for many women, it is fundamentally a metabolic story. The condition is closely tied to insulin resistance, excess weight, lipid imbalances, and a higher risk of type 2 diabetes.

That is why a new clinical trial, registered on ClinicalTrials.gov under the identifier NCT07616037, has caught the medical community's attention. Hosted by Zhongshan Hospital at Fudan University in Shanghai, this Phase 2 study plans to enroll 30 women diagnosed with PCOS.

What exactly are they testing?

Researchers are evaluating HEC88473, a dual GLP-1 and FGF21 receptor agonist. Simply put, this compound targets two pathways simultaneously to regulate blood sugar, fat metabolism, and insulin sensitivity.

The term "GLP-1" is already widely recognized thanks to popular medications for type 2 diabetes and obesity. Consequently, any new research in this area quickly makes headlines. However, it is crucial to remain objective: HEC88473 is not an Ozempic clone, nor is it a ready-made cure for PCOS. It is an experimental drug just beginning its clinical evaluation in this specific patient group.

Why a metabolic approach matters for PCOS

According to the World Health Organization, PCOS affects approximately 10–13% of women of reproductive age. For a significant portion of these patients, the condition involves not only hormonal disruptions but serious metabolic dysfunctions.

Modern medicine is increasingly looking at PCOS through a broader lens. It is no longer seen solely as an ovarian problem, but as a complex condition where the hormonal and metabolic systems are deeply intertwined. The 2023 International Evidence-based Guideline for PCOS also places a strong emphasis on managing metabolic risks and personalizing patient care.

What we already know about HEC88473

HEC88473 has some early clinical data in another medical context. The drug was previously studied in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and type 2 diabetes. In those trials, it demonstrated an ability to influence liver fat, blood glucose levels, insulin resistance, and lipid profiles.

However, these findings cannot be automatically applied to PCOS. Women with polycystic ovary syndrome represent a distinct clinical group with unique goals: regulating the menstrual cycle, managing hyperandrogenism, preserving fertility, and achieving long-term weight control. The new Shanghai trial is designed precisely to determine whether the drug has clinical value in this complex context.

What doctors are warning against

At this stage, no one can claim that HEC88473 effectively treats PCOS. There is no proof yet that it improves cycles, lowers androgen levels, increases pregnancy chances, or is safe for broad use among these patients. Registering a trial and recruiting participants is not a guarantee of clinical efficacy.

The real value of this news lies elsewhere: it highlights a global shift in how science approaches PCOS. The condition is steadily moving beyond the confines of traditional gynecology. If new metabolically targeted therapies prove their worth in large, high-quality trials, it could radically change the standard of care for women. But reaching those conclusions will still take a significant amount of time.

Primary source: ICHGCP.NET: NCT07616037.
Additional context: WHO: Polycystic ovary syndrome; 2023 International Evidence-based Guideline for PCOS; Journal of Hepatology: HEC88473 in MASLD and type 2 diabetes.

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled “Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products.” FDA is issuing this guidance as part of its Real-World Evidence (RWE) Program for drugs and to satisfy, in part, the mandate under the Federal Food, Drug, and Cosmetic Act (FD&C Act) to issue guidance about the use of RWE in regulatory decision making.

This guidance discusses the applicability of FDA’s investigational new drug application (IND) regulations to various clinical study designs that utilize real-world data (RWD) and clarifies the Agency’s expectations regarding clinical studies using RWD submitted to FDA in support of a regulatory decision regarding the effectiveness or safety of a drug that are not subject to the IND regulations.

This guidance finalizes the draft guidance of the same title issued on December 9, 2021.

Download a copy of the Guidance.

Source: the F.D.A.

PureTech is recruiting patients for the clinical trial of LYT-200 in patients with relapsed/refractory acute myeloid leukemia (AML), or with relapsed/refractory, high-risk myelodysplastic syndrome (MDS).

In Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), immature blood cells are overproduced, leading to less mature blood cells.  This causes anaemia, with underlying increased risk for infection and bleeding (MD Anderson Cancer Center, 2023).  Chemotherapy, radiation and/or autologous treatments are among possible causes of MDS or AML in up to 10% of patients.

No available therapies can currently cure most of patients suffering from MDS and AML, which calls for urgent development of new medicines.

This  open-label, non-randomized, multi-center, phase 1, dose escalation study includes patients with AML relapsed/refractory to at least one line of prior therapy, with or without an allogeneic stem cell transplant, or in patients with a documented diagnosis of relapsed/refractory, high-risk myelodysplastic syndrome (MDS) post at least one line of treatment and for whom no standard therapy that may provide clinical benefit is available. 

The study commenced on December 12, 2022. The indicative completion of the clinical trial will be expected on May 1, 2025.

Among primary outcome measures are the Incidence of Treatment-Emergent Adverse Events [Safety and RP2D determination] and Evaluation of safety parameters including treatment emergent adverse events as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, ECG, ECHO/MUGA, ECOG status.

The study will take place at several research sites in the United States: Baptist Health South Florida-Miami Cancer Institute, Miami; Cedars-Sinai Medical Center, Los Angeles; University of California Irvine Medical Center, Orange.

Among the inclusion criteria are

1. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2,

2. Patients are able and willing to comply with study procedures as per protocol, including bone marrowbiopsies,

3. Patients with a documented diagnosis of high-risk myelodysplastic syndrome (MDS), whose disease is relapsed/refractory, post at least one line of treatment based on the revised International Prognostic Scoring System (IPSS-R) and for whom no standard therapy that may provide clinical benefit is available and

4. Patients with morphologically documented primary or secondary AML by the World Health Organization(WHO) criteria, whose disease is relapsed/refractory to at least one line of prior therapy, with or without an allogeneic stem cell transplant and for whom no standard therapy that may provide clinical benefit is available or for patients who decline available standard of care can be enrolled into this research.

The page dedicated to this clinical trial that provides research sites contacts and more detailed information regarding the inclusion and the exclusion criteria can be found here: https://ichgcp.net/clinical-trials-registry/NCT05829226.

Cancer Research UK in collaboration with University of Manchester, University of Birmingham, Royal Marsden NHS Foundation Trust, and Hoffmann-La Roche are commencing recruitment into the clinical trial that is looking at a drug called entrectinib. The researchers plan that the study duration will be from April 2023 till October 2029.

Entrectinib is approved as standard of care treatment for adult patients with non-small cell lung cancer (NSCLC) which have a particular molecular alteration called ROS1-positive, and patients 12 years of age or older with solid tumours which have another type of change in the cancer cells.

This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Investigators now wish to find out if it will be useful in treating patients with other cancer types which have the same molecular alteration (ROS1-positive).

If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future. This trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.

The study will take place at the several research sites around in the UK:

• Belfast City Hospital, Belfast, United Kingdom;
• University Hospital Birmingham, Birmingham, United Kingdom;
• Birmingham Children's Hospital, Birmingham, United Kingdom;
• Bristol Royal Hospital for Children, Bristol, United Kingdom;
• Bristol Haematology and Oncology Centre, Bristol, United Kingdom;
• Addenbrooke's Hospital, Cambridge, United Kingdom;
• Velindre Cancer Centre, Cardiff, United Kingdom;
• Western General Hospital, Edinburgh, United Kingdom;
• The Beatson Hospital, Glasgow, United Kingdom;
• Royal Hospital for Children Glasgow, Glasgow, United Kingdom;
• Leeds General Infirmary, Leeds, United Kingdom;
• Leicester Royal Infirmary, Leicester, United Kingdom;
• Alder Hey Hospital, Liverpool, United Kingdom;
• The Royal Marsden Hospital, London Borough of Sutton, United Kingdom;
• University College London Hospital, London, United Kingdom;
• Guy's Hospital, London, United Kingdom;
• Great Ormond Street Hospital, London, United Kingdom;
• Royal Manchester Children's Hospital, Manchester, United Kingdom;
• The Christie Hospital, Manchester, United Kingdom;
• Great North Children's Hospital, Newcastle, United Kingdom;
• Freeman Hospital, Newcastle, United Kingdom;
• Churchill Hospital, Oxford, United Kingdom;
• John Radcliffe Hospital, Oxford, United Kingdom;
• Weston Park Hospital, Sheffield, United Kingdom;
• Southampton General Hospital, Southampton, United Kingdom;
• Clatterbridge Cancer Centre, Wirral, United Kingdom.

The page dedicated to this clinical trial inclusion and exclusion criteria, as well as th esites' contacts can be found here: https://ichgcp.net/clinical-trials-registry/NCT05770544

This study will evaluate safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects on GSBR-1290 in healthy overweight/obese volunteers (HOV). This study includes 3 planned cohorts. Participants will receive multiple-ascending doses of GSBR-1290 or Placebo from Day 1 to Day 28.

The clinical trial started in January 9, 2023 and will continue throughout September 21, 2023.

Incidence, severity and relationship of AE/SAE, vital signs, laboratory measures and ECG to assess safety and tolerability of multiple oral doses of GSBR-1290 in HOV.

Inclusion Criteria:

• Provided evidence of a signed consent.
• Age ≥ 18 and ≤ 75 years.
• Healthy overweight/obese adult men and women with body mass index ≥ 27. and ≤ 40 kg/m2.
• No nicotine use.
• Have a suitable venous access for blood sampling.

Exclusion Criteria:

1. History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic or neurological disease, including any acute illness or major surgery within the major 3 months
2. A sitting BP after resting for 5 minutes > 160mm Hg systolic or > 100 mm Hg diastolic or an apical pulse rate <50 or >100 beats per minute.
3. Evidence of abnormality on the screening visit ECG, or a history of known arrhythmia or prolonged QTcF pr prolonged QRS interval
4. Liver function test results elevated > 2.0-fold above the ULN for gamma gutamyl transferase, alkaline phosphatase, aspartate aminotransferase or alanine aminotransferase. Bilirubin above the ULN
5. Estimated glomerular filtration rate < 60mL/min/1.73 m2 body surface area
6. Known hypersensitivity to any of the study drug ingredients
7. Any other condition or prior therapy that would make the participant unsuitable for this study

The locations are the Anaheim Clinical Trials, Anaheim, California, United States; ProSciento, Inc, Chula Vista, California, United States; QPS Miami Research Associates, Miami, Florida, United States; Progressive Medical Research, Port Orange, Florida, United States. For contact details visit: https://ichgcp.net/clinical-trials-registry/NCT05762471

Areteia Therapeutics is commencing recruitment for the clinical trial of Dexpramipexole in adolescents and adults with severe eosinophilic asthma.

The trial officially began on the January 30, 2023 in several US research sites in California, Florida, Missouri, Oklahoma, and it is planned to complete by December 2025.

This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.

The potential participants must be ≥12 years of age at randomization with documented physician diagnosis of asthma for ≥12 months. They must satisfy all the below (items a to c):

a). Participants who have received asthma controller medication with medium or high dose inhaled corticosteroids (ICS; ≥500 μg/day fluticasone propionate dry powder formulation daily or clinically comparable, per Global Initiative for Asthma (GINA) 2021) on a regular basis for at least 12 months prior to screening.

b). Documented treatment with a stable dose of either medium or high dose ICS for at least 3 months prior to Visit 1. The ICS may be contained within an ICS/LABA (long-acting β2 agonist) combination product. Daily oral corticosteroids are an allowed concomitant medication; participants on daily oral corticosteroids must be on a stable dose for 3 months before Screening Visit 1.

c) Use of one of more additional daily maintenance asthma controller medications according to standard practice of care is required. Use of a stable dose of any additional asthma controller medications must be documented for at least 3 months prior to screening.

For more detailed inclusion and exlcusion criteria, as well as for the research sites contact details, please visit: https://ichgcp.net/clinical-trials-registry/NCT05763121

DeuterOncology is recruiting patients for the clinical trial of Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours.

This study is a first-in-human, open-label, 2-part, Phase 1 dose escalation study of DO-2, administered orally to patients with advanced or refractory solid tumours, with MET aberrations, and no available, approved therapeutic alternative.

In Part 1, a Simon Design 3 accelerated titration design will be followed. One patient will be enrolled per cohort, until grade 2 toxicity is observed. Three sequential patients per cohort will be enrolled thereafter, with a minimum of 1 week between first dose administration in the first patient and the subsequent ones, in those latter cohorts.

The indicative duration of the clinical trial is from December 20, 2022 till June 2024.

Among primary outcome measures are the Determination of the Maximum Tolerated Dose (MTD) and The MTD in milligram is defined as the highest dose at which less than one third of the subjects in a dose level cohort experience DLT.

The study will take place at the Institut Roi Albert II - UC Louvain, Bruxelles, Belgium; UZA, Edegem, Belgium; Erasmus Medical Centre, Rotterdam, Netherlands.

Potential study participants must have:

• 18 years or older

• histologically or cytologically confirmed advanced or refractory solid tumour and no longer eligible for approved, available standard therapies. Tumour types must have:

  1. proven MET activating mutations, determined by previous next generation sequencing (NGS), whole exome sequencing (WES), whole transcriptome sequencing (WTS) or other genomic analysis methods, or
  2. proven amplification (≥ 10 copies) on archived tumour tissue. or
  3. Hereditary Renal Papillary Cancer
      
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• adequate bone marrow function, without the support of cytokines
• adequate liver function
• adequate renal function
• agree to follow the contraception requirements of the trial
• signed informed consent, indicating study patients understand the purpose of and procedures required for the study and are willing to participate in the study.

Whereas excluded from participation will be any patient who have any of the following:

• major surgery within 3 weeks before enrollment
• chemotherapy (in the case of nitrosoureas and mitomycin C within 6 weeks), radiotherapy, immunotherapy, or any other study drug within 3 weeks before study drug administration
• antibody based cancer therapy within 4 weeks before administration of the first dose of DO-2

• patients with brain metastases are excluded unless all of the following criteria are met:

  1. CNS lesions are asymptomatic and previously treated
  2. No ongoing requirement for corticosteroids as therapy for CNS metastases
  3. Imaging demonstrates stability of disease > 28 days from last treatment for CNS metastases
      
• leptomeningeal involvement (leptomeningeal carcinomatosis)
• history of uncontrolled heart disease including unstable angina, congestive heart failure, myocardial infarction within preceding 12 months, clinically significant rhythm or conduction abnormality, congenital long QT syndrome, obligate use of a cardiac pacemaker, QTc at screening greater than 450 milliseconds in males and greater than 470 milliseconds in females
• uncontrolled arterial hypertension despite appropriate therapy
• positive pregnancy test (urinary beta-hCG) at screening (applicable to women of child-bearing potential who are sexually active)
• mental status alteration or history of major psychiatric illness, which may potentially impair patient's compliance with study procedures
• signs and symptoms of active infection requiring systemic therapy
• other medical condition (e.g. pre-existing kidney dysfunction) that in the opinion of the investigator makes it undesirable for a patient to participate

The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT05752552

The company Arecor Limited is commencing recruitment for the clinical trial of the AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study. The location is Austria.

The trial officially began on the February 17, 2023 and is planned to complete on November 25, 2023.

This is a phase 1, single dose, randomised, double-blind, two-way crossover study to compare ultra-rapid-acting concentrated insulin aspart AT278 (U500/mL) with standard insulin aspart NovoRapid® (U100/mL) in participants with T2D. Participants and Investigators will be blinded to both study interventions. Humulin® R U-500 (U500/mL), a highly concentrated regular human insulin, will be used as an open-label comparator.

The population that can be enrolled into this study includes:

• Diagnosis of type 2 diabetes for at least 180 days prior to the day of screening 
• Haemoglobin A1C (HbA1c) concentration of ≤9.5% (≤80 mmol/mol) at screening.
• BMI within the range of 25 - 45 kg/m2 (both inclusive)
  
  Exclusion Criteria:
  - Known or suspected hypersensitivity to IMPs or related products
  - Clinically significant concomitant disease or abnormal lab values
  - Severe asthma or chronic obstructive pulmonary disease (GOLD III and IV), or lower if requiring high dose of corticosteroids or beta2-adrenergic agonists.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05754424

The company Hong Kong Children's Hospital is enrolling patients into the clinical trial investigating Quadruple Immunotherapy for Neuroblastoma.

This is a single-arm clinical trial to evaluate the efficacy and safety of quadruple immunotherapy with natural killer (NK) cells, anti-GD2 antibody, cytokines (interleukin-2 (IL-2) and granulocyte-macrophage colony stimulating factor (GM-CSF)) and retinoid X receptor gamma (RXRg) agonist spironolactone for paediatric patients with relapsed or refractory neuroblastoma.

The trial is designed to enroll male and female 18 Years and younger and is being conducted in the Hong Kong Children's Hospital. The study started on January 1, 2022.

The patients that can be enrolled into this study include:

• relapsed or refractory neuroblastoma
• Adequate organ function: creatinine clearance ≥40 ml/min/1.73m2, total bilirubin ≤3 times upper limit of normal and ALT ≤500 IU/L, left ventricular shortening fraction ≥25%, and oxygen saturation ≥92% in room air
• Karnofsky or Lansky performance status score ≥50
• Has an appropriate HLA-haploidentical NK-cell donor available.
  
  Exclusion Criteria:
  
  - Pregnant or lactating woman
  - HIV infection
  - Patients for whom conventional treatment is deemed more appropriate
  - Patients who are unlikely to benefit, e.g., terminal malignancy with life expectancy <1 month.

This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05754684

The research company EDAP TMS S.A is conducting the clinical trial Evaluation of the Efficacy of HIFU Treatment on Rectal Endometriosis Symptoms (ENDO-HIFU-R2).

Rectal endometriosis (RE) induces lesions associated with painful symptoms that can alter quality of life. High Intensity Focused Ultrasound (HIFU) is a non-invasive ablative procedure using a high-intensity ultrasound probe to induce tissue devitalization using acoustic cavitation and thermal ablation. Focal One® is a transrectal HIFU device, which is validated to treat prostatic cancer. In this comparative, randomized, double blind study , the primary objective is to evaluate the efficacy of the HIFU treatment of rectal endometriosis with Focal One® HIFU device on the Acute Pelvic Pain 3 months after HIFU treatment, in comparison to a Sham group.

It is planned to include 60 participants.

Actual study start date is February 3, 2023. The researchers expect to complete the study by February 1, 2024.

Inclusion criteria:

• Patient 18 years of age or older,
• Rectal endometriosis on preoperative imaging with no other digestive location,
• Symptomatic patient (Acute pelvic pain > 3), in failure of drug treatment,
• Endometriotic lesion visible on ultrasound and confirmed on MRI,
• Centralized MRI, reviewed and validated by the MRI review committee,
• No current pregnancy and no pregnancy plan during the study period,
• Patient agreeing not to change her hormonal treatment throughout the study period,
• Patient accepting the constraints of follow-up defined in the framework of the study,
• Patient affiliated to French health insurance.

Exclusion Criteria:

• Ongoing urogenital infection,
• Anorectal anatomy incompatible with HIFU treatment,
• Overall pain level considered intolerable by the patient and making a potential 3-months delay management impossible,
• History of segmental rectal resection or discoid resection,
• Patient with an implant located less than 1 cm from the treatment area,
• Inflammatory disease of the colon,
• Allergy to latex,
• No scheduled endometriosis procedures during study follow-up,
• Treatment of endometriosis in the context of pregnancy desire for which a 3-month delay is not appropriate
• Patient with contraindications to MRI,
• Patient who has already received HIFU treatment for a rectal endometriotic lesion,
• Patient who does not speak or read French,
• Patient deprived of liberty following a judicial or administrative decision,
• Patient in labor or nursing,
• Patient under guardianship or curatorship.

The study will take place in several research sites in the following locations: Aix-en-Provence, France; Angers, France; Bordeaux, France; Clermont-Ferrand, France; Le Kremlin-Bicêtre, France; Lille, France; Lyon, France; Paris, France; Strasbourg, France. For more details please visit: https://ichgcp.net/clinical-trials-registry/NCT05755958

The company Northwell Health is enrolling patients into the clinical trial investigating Changes in Penile Firmness With Low-Intensity Shockwave Therapy (LiST).

Patients presenting with erectile dysfunction are often found to have increased corporal firmness on elastography. We hypothesize that this corporal firmness reflects reversable changes that can be altered by Low-Intensity Shockwave Therapy (LiST). In this pilot study patients found to have increased corporal firmness will be treated with LiST.

The study is being done to find out if low-intensity shockwave therapy can improve penile blood flow and restore sexual function in men with impaired erectile function.

The trial is designed to enroll Male 18 Years to 64 Years and is being conducted in the Dr. Gilbert's Office, Great Neck, New York, United States; The Smith Institute for Urology, Lake Success, New York, United States.

The study start date is March 5, 2023.

Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Men aged 18-64 4. Sexually active men and evidence of increased firmness on elastography during their standard evaluation for erectile dysfunction.

Exclusion Criteria: 1. Within two weeks of Visit 1 using erectogenic medications including PDE5 inhibitors and/or penile injection therapy 2. Presence of a penile implant. 3. Presence of cardiac pacemaker or defibrillator 4. Patients who are using devices which are sensitive to electromagnetic radiation. 5. Screening ultrasound positive for testicular cancer 6. Presence of untreated prostate cancer 7. Patients with severe coagulation disorders 8. Patient that in the opinion of the Principal Investigator would be non-compliant with the study

This page provides a more detailed overview of this clinical trial: https://ichgcp.net/clinical-trials-registry/NCT05756803

Aelis Farma is starting a new clinical trial of Phase 1/2 Trial of AEF0217 in Participants With Down Syndrome.

AEF0217-102 clinical trial assesses the safety, tolerability, plasma exposure and preliminary indications of pharmacodynamic activity of AEF0217 in female and male adult participants with Down syndrome between 18 and 35 years old. The trial AEF0217-102 is a double-blind, randomized, placebo-controlled, multiple-dose, 4-week phase 1/2 study. After a screening period, the participant will be randomised and will take an oral dose of AEF0217 0.2mg or placebo once a day for 28 days.

The clinical trial started in December 15, 2022 and will continue throughout June 2023.

The population that can be included into this trial is:

• Male or female of age ≥18 to ≤35 years, with weight ≥50 to ≤90 kg., with BMI ≥18.5 to ≤30 kg/m2, and having clinical diagnosis of Down syndrome (full trisomy 21 and translocations) documented by chromosomal analysis (karyotyping). Participants must understand and accept the trial procedures, shall be independently mobile and have sufficient vision and hearing to participate in the trial evaluations. 
• Clinical Evaluation of Language Fundamentals Preschool-2 (CELF Preschool-2) test score ≥7.
•  IQ >40 measured with the Kaufman Brief Intelligence Test (KBIT).
• Must have a parent or other reliable caregiver who agrees to accompany the participant to all clinic visits and be available for a telephone visit, provide information about the participant as required by the protocol, and ensure compliance with the medication schedule and protocol requirements.
• Vital signs, electrocardiogram (ECG), and safety laboratory parameters must be within normal ranges or without clinically relevant abnormalities except for: 1. Stable type 1 or type 2 diabetes, i.e., HbA1c level ≤6.5%, provided participants are monitored regularly prior to and during the trial to ensure adequate glucose control. 2. Hypothyroidism provided participants are euthyroid and stable on treatment for at least 6 weeks prior to screening.
  
  Excluded will be any patient with any of the following symptoms/states:
  - Pregnant or nursing female.
  - Mosaic Down syndrome.
  - Active or clinically relevant conditions that could, in the investigator's judgment, affect absorption, distribution, or metabolism of the trial intervention (e.g., inflammatory bowel disease, gastric or duodenal ulcers).
  - Clinically relevant obstructive pulmonary disease or asthma that is untreated or not controlled by treatment within 6 weeks of screening or being treated with oral steroids.
  - Severe obstructive sleep apnea. - Recent (≤1 year) or ongoing hematologic or oncologic disorders (mild anemia is allowed).
  - Personal history of infantile spasms/convulsions/epilepsy, severe head trauma, or CNS infections (e.g., meningitis), except for a single isolated febrile seizure.
  - Clinically relevant unstable gastrointestinal, renal, hepatic, endocrine, or cardiovascular system disease.
  - Current Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis including autism spectrum disorder or any primary psychiatric diagnosis.
  - Treatment with medication known to induce CYP3A4/5 P450 isozymes. - Intake of vitamin supplements, catechins, or products containing epigallocatechin gallate (EGCG) (e.g., TEAVIGO, Mega Green Tea Capsules Life Extension, or Font-UP Grand Fontaine Laboratories) currently or during the 3 months prior to the screening visit.
  - Symptoms of early dementia as assessed by the National Task Group-Early Detection Screen for Dementia (NTG-EDSD).
  - Disclosure of drug or alcohol abuse during medical interview/anamnesis at screening and/or positive urine test for alcohol or drugs of abuse at screening or/and baseline.
  - Epileptiform abnormalities (excluding isolated sharp waves and beyond those expected for age) in the screening EEG performed over 10 minutes with concurrent video recording and evaluated by an expert. - Participants with a history of suicide attempt or deliberate self-harm due to suicidal ideation. Suicidal ideation (even in the absence of suicide attempt or deliberate self-harm) during the 12 months prior to screening. Assessed by 3 specific questions on suicidal ideation, suicidal behavior, and any self-injurious behavior.
  - Known hypersensitivity to any drug.
  - Participants with clinically significant illness from 2 weeks prior to screening until Day -1.
  - Covid-19 positive PCR test and symptoms within the last 10 days prior to Day -1.
  - History of or current life-threatening disease.
  - Any other clinically relevant concomitant disease or condition or finding at screening that in the investigator's judgment could jeopardize the participant's safety or interfere with, or the treatment thereof might interfere with, the conduct of the trial and related procedures and/or might bias interpretation of the trial results.

The study location is the Hospital del Mar Medical Research Institute (IMIM), Barcelona, Catalonia, Spain. For more details: https://ichgcp.net/clinical-trials-registry/NCT05748405

The company Areteia Therapeutics is commencing recruitment for the clinical trial of the A 24-week Clinical Trial to Study the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma.

The trial that takes place in several serearch sites in the USA officially began on the January 30, 2023 and is planned to complete on July 2024.

The purpose of this study is to evaluate dexpramipexole as an add-on oral therapy in participants with inadequately controlled eosinophilic asthma to evaluate improvements in lung function, asthma control, and quality of life. In addition, the study will further evaluate the safety and tolerability of dexpramipexole in participants with eosinophilic asthma.

The population that can be enrolled into this study includes: 

1. Male or female ≥12 years of age at randomization who signed a written infromed consent to participate.

   Asthma-related criteria

2. Documented physician diagnosis of asthma for ≥12 months.
3. Participants requiring at a minimum daily low dose inhaled corticosteroids (ICS; ≥100 μg/day fluticasone propionate dry powder formulation daily or clinically comparable, per GINA 2021), plus one or more additional daily maintenance asthma controller medications, eg, long-acting β2 agonist (LABA), leukotriene antagonist, theophylline, long-acting muscarinic antagonists, cromolyn/nedocromil. Use of daily ICS must be for at least 12 weeks prior to Screening Visit 1 and the doses of all controller medications must be stable for at least 4 weeks prior to Screening Visit 1.
4. Pre-BD FEV1 ≥40% and <80% of predicted at Screening.
5. Bronchodilator reversibility, as evidenced by ≥12% and ≥200 mL improvement in FEV1, 15 to 30 minutes following inhalation of 400 μg (four puffs) of albuterol/salbutamol (≥12% and ≥160 mL for ages 12 to 17).Participants who do not meet the bronchodilator reversibility inclusion criterion but have ≥10% and ≥160 mL reversibility, may repeat the reversibility spirometry assessment once during the Screening Period, at an unscheduled visit at least 7 days prior to baseline.
6. ACQ-6 ≥1.5 at Screening.
7. Eosinophil count of ≥0.30x10⁹/L at Screening Visit 1. If the initial value is between 0.250x10⁹/L to 0.299x10⁹/L, then this may be repeated once at an unscheduled visit (prior to Screening Visit 2).
8. Negative urine pregnancy test for women of childbearing potential (WOCBP; after menarche) at Screening and Baseline.

For exclusion criteria and research sites contact details kindly follow the link: https://ichgcp.net/clinical-trials-registry/NCT05748600

The company NIZO Food Research in cooperation with Kappa Bioscience AS  is commencing recruitment for the clinical trial of the Antioxidant and Immune Effects of Vitamin K2. 

The conditions are Oxidative Stress, Inflammation. A new clinical trial is recruiting patients in the Netherlands. The trial officially began on the November 15, 2022 and is planned to complete on May 2023.

The aim of the study is to obtain insight into a dose-dependent effect of vitamin K2 on oxidative stress and specific markers of the immune system.

The population that can be enrolled into this study includes:

• Self-reported postmenopausal (at least one year after the final menstruation) - BMI ≥25 and ≤32 kg/m2;
• Plasma dp-ucMGP concentration in highest 50-66% of the screened population;
• Non-smoking, defined as not smoking currently and not having smoked (at all) in the year before study start;
• Healthy as assessed by the health questionnaire and according to the judgment of the study physician;
• Voluntary participation;
• Having given written informed consent;
• Willing to comply with study procedures.
  
  Exclusion Criteria:
  - Plasma dp-ucMGP concentration >1000 pmol/L at screening
  - Treatment with oral antibiotics within 2 months of the start of the study
  - Any vaccination in the month before study start or any scheduled vaccination during the study period
  - Use of antioxidant or vitamin K and D supplements in the month before the start of the study;
  - Use of aspirin or medication with established antioxidant or anti-inflammatory properties;
  - Use of medication that interferes with vitamin K or blood coagulation; - Use of statins to reduce level of low-density lipoprotein cholesterol in the blood;
  - Hyperlipidaemia, diabetes, hypertension, intestinal disease, diseases with an inflammation component;
  - Hormone replacement therapy in women;
  - Follow a vegetarian or vegan diet;
  - Participation in any clinical trial including blood sampling and/or administration of substances up to 30 days before day 1 of this study;
  - Alcohol consumption for men >28 units/week and >4/day; for women: >21 units/week and >3/day;
  - Reported unexpected weight loss or weight gain of >3 kg in the month prior to pre-study screening, or intention to lose weight during the study period;
  - Reported slimming or medically prescribed diet;
  - Recent blood donation (<1 month prior to Day 01 of the study); - Not willing to give up blood donation during the study.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05675163.

The company OM Pharma is commencing recruitment for the clinical trial of the OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness. This is a randomised, placebo-controlled, 3-Arm, double-blind, multicentre, phase 4 Study to Assess the Efficacy of OM-85 (Broncho-Vaxom) Short- and Long-Term Treatment vs. Placebo in the Prevention of Respiratory Tract Infections in Children Aged Between 6 Months and 5 Years With Wheezing Lower Respiratory Illness.

The conditions include respiratory tract infections and wheezing lower respiratory illness. The trial officially began on the December 12, 2022 and is planned to complete by June 30, 2025.

This study will assess the efficacy and safety of OM-85 compared to placebo in reducing the number of respiratory tract infections (RTIs) in children aged between 6 months and 5 years.

The population that can be enrolled into this study:

• Children of either gender aged between 6 months and 5 years, inclusive.
• For children ≥1 year of age, ≥4 RTIs (as reported by parents or LAR of subject), including ≥2 episodes of wLRIs (including ≥1 triggering hospitalisation or medical visit) within 12 months prior to enrolment. OR
• For children  <1 year of age, ≥2 RTIs (as reported by parents or LAR of subject), including ≥1 episode of wLRIs (including ≥1 triggering hospitalisation or medical visit) within 6 months prior to enrolment.
• Parents or LAR of subject have provided the appropriate written informed consent. Written informed consent must be provided before any study-specific procedures are performed including screening procedures.
  
  The following patients cannot participate:
• With anatomic alterations of the respiratory tract.
• With other respiratory chronic diseases (e.g., tuberculosis, cystic fibrosis).
• With any autoimmune disease.
• Those having HIV infection or any type of congenital or iatrogenic immune deficiency (including IgA deficiency).
• With congenital heart disease.
• With haematologic diseases.
• With liver or kidney failure.
• New-borns before 34 weeks of gestational age.
• With malnutrition as per World Health Organization (WHO) definition.
• With any known neoplasia or malignancy.
• Undergoing treatment with the following medications:
  1. Systemic or oral steroids (e.g., oral prednisolone) within 4 weeks prior to study enrolment.
  2. Previous and/or concomitant immunosuppressants, immunostimulants, or gamma globulins within 6 months prior to study enrolment.
• With previous use within last 6 months of enrolment or ongoing use of bacterial lysates.
• Underwent any major surgery within the last 3 months prior to study enrolment.
• Having known allergy or previous intolerance to investigational medicinal products (IMP).
• Having any other clinical conditions, that in the opinion of the Investigator, would not allow safe completion of the clinical study.
• Whsose other household members have previously been randomised in this clinical study.
• Whose families expected to relocate out of study area within 24 months of the initiation of the study.
• Being currently enrolled in or has completed any other investigational device or drug study or receiving other investigational agent(s) within  <30 days 30 days prior to screening.
• With parents or legally acceptable representative (LAR) who do not have access to internet connection.

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05677763.